{
    "title": "The comparative effectiveness of 55 interventions in obese patients with polycystic ovary syndrome: A network meta-analysis of 101 randomized trials",
    "journal": "PLoS ONE",
    "publication_date": "2021",
    "abstract": "Polycystic ovary syndrome (PCOS) affects up to 18% of reproductive-age females. The prevalence of obesity in PCOS patients reaches up to 80%, which is 2-fold higher than the general population. The present study aimed to compare the effectiveness of 55 pharmacological interventions across 17 different outcomes in overweight/obese PCOS patients with hyperandrogenism manifestations for both short- and long-term follow-ups. A comprehensive literature search was performed on PubMed, Scopus, Embase, Science Direct, Web of Science, and Cochrane CENTRAL for randomized controlled trials comparing any conventional pharmacological intervention as a monotherapy or a combination in overweight/obese patients with polycystic ovary syndrome and hyperandrogenism manifestations. Extracted data included three main parameters; I. Anthropometric parameters (BMI, Waist and Hip circumferences, and Waist/HIP ratio), II. Hormonal parameters (FSH, LH, FSG, SHBG, Estradiol, Total Testosterone, Free testosterone, DHEAS, Androstenedione), and III. Metabolic parameters (Total Cholesterol, LDL-C, HDL-C, Triglycerides, Fasting glucose, Fasting glucose, HOMA-IR). Critical appraisal and risk of bias assessments were performed using the modified Jadad scale, and the overall quality of this network meta-analysis was evaluated according to the CINeMA framework. We performed both a pairwise meta-analysis and a network meta-analysis to evaluate the effect sizes with 95% CI, and we calculated the surface under the cumulative ranking curve (SUCRA) for each intervention. Our final search on May 15 Current evidence demonstrated the superiority of flutamide in improving both metabolic and hormonal parameters, and the higher efficacy of cyproterone-acetate+ethinylestradiol only in improving hormonal parameters. Nearly all interventions were comparable in female hormones, FGS, HDL, glucose, and insulin levels improvements.",
    "body": "1. Introduction  Polycystic ovary syndrome (PCOS) is a complex endocrinal disorder affecting up to 18% of young females [ 1 ]. The syndrome comprises of oligomenorrhea, hyperandrogenism, and polycystic findings in ovarian ultrasound [ 2 ]. While patients usually present with infertility or menstrual abnormality, they are highly susceptible to metabolic disorders such as obesity, hyperinsulinemia, and insulin resistance; thus, increasing the risks of diabetes, cardiovascular diseases, and uterine cancer -especially in overweight and obese patients [ 3 ]. For instance, the prevalence of obesity in PCOS patients reaches up to 80%, which is 2-fold higher than the general population [ 4 ].  The pathophysiology of PCOS is still unclear, but evidence suggests a mixture of environmental factors and genetic susceptibility [ 5 ]. One of the central pathogenic markers is the elevated Luteinizing Hormone (LH) levels that stimulate theca cells to produce androgens, and not enough Follicle Stimulating Hormone (FSH) to convert these androgens to estrogens [ 5 ]. Many hypotheses were presented explaining this high LH/FSH ratio including the frequent Gonadotropin-Releasing Hormone (GnRH) pulses, increased insulin resistance, and hyperinsulinemia [ 6 ].  Pharmacological interventions mainly involve: oral contraceptives, antiandrogens, oral hypoglycemics, insulin sensitizers, ovulation induction agents, and conventional obesity treatments [ 6 ]. The recently used combined oral contraceptives such as ethinylestradiol+cyproterone acetate, ethinylestradiol+desogestrel, and ethinylestradiol+drospirenone presented promising results in reducing androgen levels and regulating menstruation [ 7 , 8 ].  Still, long-term use of these agents increases the risk of venous thrombosis and disrupts the metabolic parameters [ 9 ]. Hypothetically, the addition of metformin could improve glucose and lipid metabolism and reduce these severe events [ 10 ]. The problem is the required dosage of metformin can produce difficult side-effects such as nausea, diarrhea, stomach ache, and most studies measured this efficacy in the short-term [ 11 ]. On the other hand, previous pairwise meta-analyses could not address the whole range of all widely available therapies; thus, provided limited evidence to choose the most effective intervention.  Given that the symptoms upon diagnosis are usually confined to irregular menstruation or infertility, physicians may disregard the possible long-term metabolic and anthropometric disturbances [ 6 ]. Subsequently, fewer studies have focused on metabolic parameters and long-term follow-up [ 12 ]. The previous studies measured limited outcomes of specific interest, leaving the final picture unclear and incomplete [ 13 \u2013 15 ]. For PCOS is a chronic progressive disorder, the management should address the long-term efficacy.  Accordingly, we performed this network meta-analysis to compare the effectiveness of 55 pharmacological interventions across 17 different clinical and biochemical outcomes in overweight PCOS patients for both short- and long-term follow-ups.    2. Materials and methods   2.1 Search strategy and selection criteria  We followed the PRISMA statement guidelines ( S6 File \u2014PRISMA) [ 16 ] during the preparation of this systematic review and network meta-analysis and performed all steps in strict accordance with the Cochrane handbook of systematic reviews of intervention [ 17 ].  To synthesize the search strategy and the selected search terms, several analytical workshops, consultations of experts in the field and extensive review of the literature were employed. Eventually, a comprehensive search was employed on PubMed, Scopus, Embase, Science Direct, Web of Science, and Cochrane CENTRAL for randomized controlled trials comparing any conventional pharmacological intervention as a monotherapy or a combination in overweight/obese patients with polycystic ovary syndrome and hyperandrogenism manifestations, using relevant keywords; (Polycystic ovary syndrome [MeSH Terms]) OR (polycystic ovary syndrome[Title/Abstract])) OR (PCOS[Title/Abstract])) OR (Stein-Leventhal syndrome[MeSH Terms])) OR (Stein-Leventhal syndrome[Title/Abstract])) OR (anovulation[MeSH Terms])) OR (anovulation[Title/Abstract])) OR (amenorrhea[MeSH Terms])) OR (amenorrhea[Title/Abstract])) OR (ovarian dysfunction[Title/Abstract])) OR (ovarian failure[Title/Abstract])) OR (Oligo-amenorrhea[Title/Abstract]))) AND (metformin[Title/Abstract])) OR (metformin[MeSH Terms])) OR (liraglutide[Title/Abstract])) OR (orlistat[Title/Abstract])) OR (orlistat[MeSH Terms])) OR (inositol[MeSH Terms])) OR (inositol[Title/Abstract])) OR (oral contraceptive[MeSH Terms])) OR (oral contraceptive*[Title/Abstract])) OR (Ethinyl estradiol[MeSH Terms])) OR (Ethinyl estradiol[Title/Abstract])) OR (ethinylestradiol[MeSH Terms])) OR (ethinylestradiol[Title/Abstract])) OR (diane[Title/Abstract])) OR (cyproterone[MeSH Terms])) OR (cyproterone[Title/Abstract])) OR (combined oral contraceptive[MeSH Terms])) OR (combined oral contraceptive[Title/Abstract])) OR (OCP[Title/Abstract])) OR (CC[Title/Abstract])) OR (marvelon[MeSH Terms])) OR (marvelon[Title/Abstract])) OR (desogestrel[MeSH Terms])) OR (desogestrel[Title/Abstract])) OR (yasmin[Title/Abstract])) OR (drospirenone[Title/Abstract])) OR (letrozole[MeSH Terms])) OR (letrozole[Title/Abstract])) OR (FSH[Title/Abstract])) OR (hMG[Title/Abstract])) OR (menotropin[MeSH Terms])) OR (menotropin[Title/Abstract])) OR (pioglitazone[MeSH Terms])) OR (pioglitazone[Title/Abstract])) OR (rosiglitazone[MeSH Terms])) OR (rosiglitazone[Title/Abstract])) OR (troglitazone[MeSH Terms])) OR (troglitazone[Title/Abstract])) OR (litraglutide[Title/Abstract])) OR (flutamide[MeSH Terms])) OR (flutamide[Title/Abstract])) OR (clomiphene[MeSH Terms])) OR (clomiphene[Title/Abstract])) OR (clomifene[Title/Abstract])) OR (clomifene[MeSH Terms])) OR (chlormadinone[MeSH Terms])) OR (chlormadinone[Title/Abstract])) OR (gonadotropin[Title/Abstract])) OR (gonadotropin[MeSH Terms])) OR (simvastatin[MeSH Terms])) OR (simvastatin[Title/Abstract])) OR (atorvastatin[Title/Abstract])) OR (atorvastatin[MeSH Terms])) OR (acarbose[MeSH Terms])) OR (acarbose[Title/Abstract])) OR (alfacalcidol[Title/Abstract])) OR (anastrozole[MeSH Terms])) OR (anastrozole[Title/Abstract])) OR (clomiphene citrate[Title/Abstract])) OR (clomiphene citrate[MeSH Terms])) OR (exenatide[MeSH Terms])) OR (exenatide[Title/Abstract])) OR (folic acid[Title/Abstract])) OR (folic acid[MeSH Terms])) OR (pure follicle-stimulating hormone[MeSH Terms])) OR (pure follicle-stimulating hormone[Title/Abstract])) OR (human menopausal gonadotropins[Title/Abstract])) OR (human menopausal gonadotropins[MeSH Terms])) OR (letrozole[MeSH Terms])) OR (letrozole[Title/Abstract])) OR (liraglutide[Title/Abstract])) OR (medroxyprogesterone acetate[MeSH Terms])) OR (medroxyprogesterone acetate[Title/Abstract])) OR (N-acetyl cysteine[Title/Abstract])) OR (N-acetyl cysteine[MeSH Terms])) OR (pioglitazone[MeSH Terms])) OR (pioglitazone[Title/Abstract])) OR (rosiglitazone[Title/Abstract])) OR (rosiglitazone[MeSH Terms])) OR (sibutramine[Title/Abstract])) from inception till 28 August 2020 and search update was conducted on March 28 th 2021 and May 15 th 2021 covering all selected databases ( S5 File\u2014Search ). All published articles were considered with no restriction in terms of language or date. We also searched the bibliography of included studies for additional relevant records. Metabolic parameters were not added to the final search terms due to its broader non-specific scope. Also, all variations for this broader search approach has been tested and evaluated.  We included all studies satisfying the following criteria:    Population: overweight/obese patients (BMI more than 25 kg/m 2 ) with polycystic ovary syndrome defined by Rotterdam, NIH, or Androgen Excess Society criteria for PCOs with a mutual presentation of obesity and hyperandrogenism across criteria; (2, 3) Intervention and Comparison: any conventional pharmacological intervention; (4) Outcomes: Extracted data included three main parameters; I. Anthropometric parameters (BMI, Waist and Hip circumferences, and Waist/HIP ratio), II. Hormonal parameters (FSH, LH, FSG, SHBG, Estradiol, Total Testosterone, Free testosterone, DHEAS, Androstenedione), and III. Metabolic parameters (Total Cholesterol, LDL-C, HDL-C, Triglycerides, Fasting glucose, Fasting glucose, HOMA-IR), and (5) Study design: blinded randomized controlled trials (RCTs). We excluded the following: 1) non-randomized trials, 2) open-label and cross-over studies 3) surgical, herbal, and supplemental interventions, and 4) studies whose data were unreliable for extraction and analysis including post hoc analyses and preliminary reports. Duplicates were removed and retrieved references were screened in two steps: the first step was to screen titles/abstracts for matching our inclusion criteria and the second step was to screen the full-text articles of eligible abstracts for eligibility to meta-analysis. Given the challenges in this unique design of the network-meta analysis, we included comparable RCTs in their methodology and quality to guarantee the assumption of transitivity and the lowest possible heterogeneity. We analyzed only well-designed blinded RCTs that applied globally recognized diagnostic criteria for PCOS. Regarding the BMI, we considered both the mean and the standard deviation (SD) in determining the eligibility of the studies\u2019 population. For instance, studies that had an average BMI above 25 but had a standard deviation that crosses the 25-mean into a lower value for some patients were excluded. Also, we separated studies with short-term follow-ups from those with long-term follow-ups in the statistical combinations. Eventually, each included intervention was administered as primary therapy in its original study. So, a critical distinction has to be made between a tertiary/off-label use of a drug and the primary use of the same drug.    It is worth mentioning that PCOS can present differently in the clinical practice that is infertility, anovulation, irregular menses, hyperandrogenism, or metabolic disturbances. Accordingly, when comparing 55 interventions, it is clear that each group of these therapies is usually administered to only address a part of the problem (i.e. Clomiphene citrate for ovulation, Rosiglitazone for insulin resistance, etc.), so it would not be fair to compare these agents to each other regarding the same outcome. With that in mind, we had two prospects when planning for this study. Firstly, we could have focused the study on the used interventions a particular PCOS phenotype (irregular menses, insulin resistance, hyperlipidemia, etc.) only. Even though this option would have been much simpler to handle, the work would have contributed more to widening the current knowledge gap. Given that PCOS has a progressive nature, it does not restrain itself to the presented phenotype, let alone that the borders that should determine different managements between various phenotypes are inevitably interleaving -implying a dire need for a much comprehensive investigation. Alternatively, we selected 17 measurable parameters that are mutual between various phenotypes and grouped them into anthropometric, metabolic, and hormonal parameters. Following, we examined the effect of each intervention on each parameter of these 17 parameters (whether this intervention is usually used to address this parameter or not, such as Clomiphene citrate effect on LDL). That is how even when intervention X has primary use for the first five parameters (with a secondary or tertiary effect on the rest) and intervention Y has primary use for the last five parameters (with secondary or tertiary effect on the rest), we can still draw an overall performance across parameters between the two interventions in an objective manner. Eventually, the data of this extensive analysis would help in drawing step-wise management for different phenotypes based on the best performing intervention across the prioritized parameters of that phenotype (such as hormonal parameters in irregular menses presentation, and metabolic-anthropometric parameters in morbid obesity presentation, and all hormonal-metabolic-anthropometric parameters in multiple severe presentations). This algorithm will further promote the clinical practice to be more data-driven instead of theory-driven regarding PCOS management.  Eight independent authors extracted the relevant data from the included studies, four authors (M.A.M., A.M., E.A.H., and M.I.A) performed the literature search and validation, then, another four authors (M.A., M.E., E.M., and O.O.) re-performed the search and validation. Disagreements were resolved through discussion and consensus among the reviewers. The screening and de-duplication were conducted through Endnote X7 and Microsoft Excel 2016. The extracted data included the following:    Baseline characteristics (Study ID, Year, Country, Intervention groups, Dosage, Sample size, Age in years, blinding, Diagnostic criteria, Follow up duration in weeks, and Resistance)    Study outcomes: I. Anthropometric parameters, II. Hormonal, and III. Metabolic parameters -as previously defined.    Critical appraisal and risk of bias assessments of the included RCTs were performed using the modified Jadad scale from Oxford University [ 18 ]. This eight-item scale was designed to evaluate randomization, blinding, dropouts, criteria of inclusion and exclusion, adverse effects, and statistical analysis ( S1 File ; S1 Table in S1 File ). The score ranges from 0 (the lowest quality) to 8 (the highest quality). Articles with scores of 4\u20138 indicate good to excellent quality, while those with 0\u20133 denote poor to low quality. The overall quality of this network meta-analysis was evaluated according to the CINeMA framework. Funnel plots were constructed to make visual assessments of possible publication bias.    2.2 Data analysis  Statistical analyses were performed using Stata 16.0 software. First, we conducted a pair-wise meta-analysis employing the IVhet random-effects model. All reported units were converted to standard SI units. All data were continuous (means and standard deviations \"SD\") and were pooled as weighted mean differences (MD) with 95% confidence intervals. Missing SD was calculated from the standard error or 95% CI or range according to Wan et al. [ 19 ] or obtained from SD of baseline and SD of change according to Cochrane 16.1.3.2 [ 17 ]. Heterogeneity between trials was examined visually and statistically through Chi-square and I2 tests: values of 0%-40%, 30%-60%, 50%-90%, and 75%-100% represented low, moderate, substantial, and considerable heterogeneity; respectively. P<0.1 was set as a level of significant heterogeneity, according to Cochrane Handbook recommendations. When considerable heterogeneity was detected, we conducted a sensitivity analysis to determine the source of heterogeneity by excluding one study at a time.  Second, a network meta-analysis was performed with a frequentist framework to compare different interventions that have no direct comparisons. We applied the node-splitting and loop-specific approaches to verify inconsistencies across the network, where a p<0.05 indicated a significant inconsistency. When no significant inconsistency was detected, we employed a consistency model; otherwise, an inconsistency model was adopted. We also utilized a global inconsistency test based on a random-effects design-by-treatment interaction model. Additionally, the surface under the curve ranking area (SUCRA) was calculated to rank different interventions for each outcome. Further, a meta-regression was conducted to examine the relationship between anthropometric, hormonal, and metabolic parameters.     3. Results   3.1 Characteristics and quality of included studies  Our updated search retrieved 23,305 unique citations from searching electronic databases. Following title and abstract screening, 408 full-text articles were retrieved and screened for eligibility. Of them, 307 articles were excluded, and 101 RCTs [ 20 \u2013 32 , 33 , 34 \u2013 43 , 44 , 45 \u2013 54 , 55 , 56 \u2013 65 , 66 , 67 \u2013 76 , 77 , 78 \u2013 87 , 88 , 89 \u2013 98 , 99 , 100 \u2013 109 , 110 , 111 \u2013 120 ] (108 reports) (n = 8,765 patients) were reviewed in detail and included in this multi-treatment meta-analysis (PRISMA flow diagram; Fig 1 ). The updated search identified 16 new study [ 121 \u2013 128 , 129 \u2013 136 ], however, they could not be added to our analysis due to the following causes: five studies failed to meet our BMI criteria [ 136 \u2013 126 ], three studies included irrelevant interventions [ 133 \u2013 135 ], two studies had an open-label design [ 127 , 128 ], two studies measured different outcomes [ 131 , 132 ], one study had a cost-effectiveness design [ 121 ], one study had a post-hoc design [ 129 ], one study had no treatment control [ 122 ], and one study included pregnant patients [ 130 ]. Additionally, the bibliography of the included RCTs was manually searched, but no further records were added. All of the included studies were performed between 1987 and 2020; 37 studies in Europe, 32 studies in the Middle East, 20 studies in North America, 8 studies in Asia, and 4 studies in South America.   10.1371/journal.pone.0254412.g001  Fig 1   A PRISMA flow diagram illustrates the search results, de-duplication, screening and the selection process.     55 different interventions were included: 22 monotherapies, and 33 combinations. The monotherapies included acarbose (ACR), alfacalcidol (ALF), anastrozole (ANZ), clomiphene citrate (CC), exenatide (EXN), folic acid (FA), flutamide (FLT) pure follicle-stimulating hormone (FSH), human menopausal gonadotropins (HMG), inositol (INS), letrozole (LET), liraglutide (LIR), metformin (MET), medroxyprogesterone acetate (MPA), N-acetyl cysteine (NAC), orlistat (ORL), pioglitazone (PGZ), placebo (PLC), rosiglitazone (RGZ), sibutramine (SBT), simvastatin (SMV), and troglitazone (TGZ).  The combinations included acarbose+clomiphene citrate (ACR+CC), alfacalcidiol+metformin (ALF+MET), atorvastatin+metformin (ATR+MET), bromocriptine+clomiphene citrate (BRM+CC), bromocriptine+metformin (BRM+MET), clomiphene citrate+dexamethasone (CC+DEX), clomiphene citrate+ketoconazole (CC+KTZ), clomiphene citrate+l-carnitine (CC+LC), clomiphene citrate+l-carnitine+metformin (CC+LC+MET), clomiphene citrate+metformin (CC+MET), clomiphene citrate+N-acetylcysteine (CC+NAC), clomiphene citrate+rosiglitazone (CC+RGZ), chlormadinone acetate+ethinylestradiol (CHA+EE), cyproterone acetate+ethinylestradiol (CPA+EE), cyproterone acetate+ethinylestradiol+metformin (CPA+EE+MET), cyproterone acetate+ethinylestradiol+metformin+orlistat (CPA+EE+MET+ORL), cyproterone acetate+ethinylestradiol+orlistat (CPA+EE+ORL), cyproterone acetate+ethinylestradiol+spironolactone (CPA+EE+SPR), dexamethasone+metformin (DEX+MET), desogestrel+ethinylestradiol (DGT+EE), drospirenone+ethinylestradiol (DPN+EE), drospirenone+ethinylestradiol+metformin (DPN+EE+MET), ethinylestradiol+flutamide+levonorgestrel (EE+FLT+LVT), ethinylestradiol+gestodene (EE+GTN), ethinylestradiol+metformin+norgestimate (EE+MET+NRG), ethinylestradiol+norgestimate (EE+NRG), folic acid+inositol (FA+INS), flutamide+metformin (FLT+MET), human menopausal gonadotropins+ leuprolide (HMG+LPR), inositol+monacolin k (INS+MNK), letrozole+metformin (LET+MET), metformin+rosuvastatin (MET+RSV), and metformin+simvastatin (MET+SMV).  A network map was formed to visually display the size of studies involved in each direct comparison for each outcome ( Fig 2 ), and a summary table was drawn to detail each included study ( Table 1 ). We divided comparisons of the same treatment into two categories based on the follow-up duration, where studies below 24 weeks grouped as a short and intermediate-term, and those from 24 weeks onward grouped as a long term. The mark (#) at the end of a treatment\u2019s abbreviation indicates a short term follow up.   10.1371/journal.pone.0254412.g002  Fig 2   Network graphs of eligible comparisons for efficacy.  The size of the circles is proportional to sample size, and the width of lines is proportional to the number of trials. Interventions: acarbose (ACR), alfacalcidol (ALF), anastrozole (ANZ), clomiphene citrate (CC), exenatide (EXN), folic acid (FA), flutamide (FLT) pure follicle-stimulating hormone (FSH), human menopausal gonadotropins (HMG), inositol (INS), letrozole (LET), liraglutide (LIR), metformin (MET), medroxyprogesterone acetate (MPA), N-acetyl cysteine (NAC), orlistat (ORL), pioglitazone (PGZ), placebo (PLC), rosiglitazone (RGZ), sibutramine (SBT), simvastatin (SMV), and troglitazone (TGZ). Acarbose+clomiphene citrate (ACR+CC), alfacalcidiol+metformin (ALF+MET), atorvastatin+metformin (ATR+MET), bromocriptine+clomiphene citrate (BRM+CC), bromocriptine+metformin (BRM+MET), clomiphene citrate+dexamethasone (CC+DEX), clomiphene citrate+ketoconazole (CC+KTZ), clomiphene citrate+l-carnitine (CC+LC), clomiphene citrate+l-carnitine+metformin (CC+LC+MET), clomiphene citrate+metformin (CC+MET), clomiphene citrate+N-acetylcysteine (CC+NAC), clomiphene citrate+rosiglitazone (CC+RGZ), chlormadinone acetate+ethinylestradiol (CHA+EE), cyproterone acetate+ethinylestradiol (CPA+EE), cyproterone acetate+ethinylestradiol+metformin (CPA+EE+MET), cyproterone acetate+ethinylestradiol+metformin+orlistat (CPA+EE+MET+ORL), cyproterone acetate+ethinylestradiol+orlistat (CPA+EE+ORL), cyproterone acetate+ethinylestradiol+spironolactone (CPA+EE+SPR), dexamethasone+metformin (DEX+MET), desogestrel+ethinylestradiol (DGT+EE), drospirenone+ethinylestradiol (DPN+EE), drospirenone+ethinylestradiol+metformin (DPN+EE+MET), ethinylestradiol+flutamide+levonorgestrel (EE+FLT+LVT), ethinylestradiol+gestodene (EE+GTN), ethinylestradiol+metformin+norgestimate (EE+MET+NRG), ethinylestradiol+norgestimate (EE+NRG), folic acid+inositol (FA+INS), flutamide+metformin (FLT+MET), human menopausal gonadotropins+ leuprolide (HMG+LPR), inositol+monacolin k (INS+MNK), letrozole+metformin (LET+MET), metformin+rosuvastatin (MET+RSV), and metformin+simvastatin (MET+SMV).      10.1371/journal.pone.0254412.t001  Table 1   Shows baseline and summary data of patients in included studies.                                Author  Year  Country  Groups  Dosage  Sample Size  Age  Blinding  Diagnostic Criteria  Folllow Up (Weeks)  Resistance  Author  Year  Country  Groups  Dosage  Sample Size  Age  Blinding  Diagnostic Criteria  Folllow Up (Weeks)  Resistance    Mean \u00b1 SD (years)  Mean \u00b1 SD (years)       Azziz et al,   2003  United States  PLC   73  29.3 \u00b1 5.6  Double  NIH Criteria  20  NA   Azziz et al,   2001  United States  PLC   73  30.1 \u00b1 6.0  Double  NIH Criteria  44  NA    TGZ  150 mg/day  78  29.3 \u00b1 5.6  TGZ  150 mg/day  78  28.9 \u00b1 5.4    TGZ  300 mg/day  77  29.3 \u00b1 5.6  TGZ  300 mg/day  77  29.2 \u00b1 5.8    TGZ  600 mg/day  77  29.3 \u00b1 5.6  TGZ  600 mg/day  78  29.0 \u00b1 5.2     Aroda et al,   2009  United States  PLC   10  27.0 \u00b1 1.0 *  Single  NIH Criteria  24  NA   Hassan et al, (a)   2001  Egypt  CC+KTZ  100 mg/day+400 mg/day  25  NA  Single  NIH Criteria  36  NA    PGZ  45 mg/day  13  28.0 \u00b1 1.0 *  CC  100 mg/day  38  NA     Hassan et al, (b)   2001  Egypt  CC+KTZ  100 mg/day+400 mg/day  12  NA  Single  NIH Criteria  36  CC   Abu Hashim et al,   2010  Egypt  LET  2.5 mg/day  123  28.3 \u00b1 2.7  Single  Rotterdam Criteria  8  CC    CC  100 mg/day  5  NA  CC+MET  150 mg/day+500 mg tid  127  26.2 \u00b1 2.2     Bridger et al,   2006  Canada  MET  750 mg bid  11  16.07 \u00b1 0.97  Double  NIH Criteria  12  NA   Brettenthaler et al,   2004  United Kingdom  PGZ  30 mg/day  17  30.2 \u00b1 1.4 *  Double  NIH Criteria  12  NA    PLC   11  16.08 \u00b1 1.39  PLC   18  30.6 \u00b1 1.1 *     Bilgir et al,   2009  Turkey  CPA+EE  2 mg/day+35 \u03bcg/day  20  24.3 \u00b1 5.7  Single  Rotterdam Criteria  12  NA   Bhattacharya et al, (24 wks)   2012  India  DGT+EE  0.15 mg/day+0.03 mg/day  58  22.24 \u00b1 4.47  Double  Androgen Excess Society criteria  24  NA    CPA+EE  2 mg/day+0.03 mg/day  56  22.32 \u00b1 4.17    CPA+EE+MET  2 mg/day+35 \u03bcg/day+1700 mg/day  20  25.2 \u00b1 4.6  DPN+EE  3 mg/day+0.03 mg/day  57  22.33 \u00b1 4.76     Bhattacharya et al, (48 wks)   2012  India  DGT+EE  0.15 mg/day+0.03 mg/day  58  22.24 \u00b1 4.47  Double  Androgen Excess Society criteria  48  NA   Benelli et al,   2016  Italy  FA+INS 1 + INS 2  200 \u03bcg bid+550 mg bid+13.8 mg bid  21  23 \u00b1 6.8  Single  Rotterdam Criteria  24  NA    CPA+EE  2 mg/day+0.03 mg/day  56  22.32 \u00b1 4.17    DPN+EE  3 mg/day+0.03 mg/day  57  22.33 \u00b1 4.76  FA  200 \u03bcg bid  25  25 \u00b1 7.3     Badawy et al, (a)   2009  Egypt  ANZ  1 mg/day  115  23.8 \u00b1 3.1 *  Single  Rotterdam Criteria  10  NA   Badawy et al, (b)   2009  Egypt  LET  5 mg/day  218  27.1 \u00b1 3.2 *  Single  Rotterdam Criteria  10  NA    CC  100 mg/day  101  25.3 \u00b1 2.9 *  CC  100 mg/day  220  29.3 \u00b1 2.9 *     Badawy et al,   2008  Egypt  CC  100 mg/day  160  24.1 \u00b1 3.1 *  Single  Rotterdam Criteria  16  CC   Chou et al,   2003  Brazil  MET  500 mg tid  14  24 \u00b1 5  Double  NIH Criteria  12  NA    HMG  75 IU/day  158  26.3 \u00b1 3.0 *  PLC   16  24.5 \u00b1 6.1     Celik et al,   2012  Turkey  MET  2000 mg/day  20  25.9 \u00b1 5.7  Single  Rotterdam Criteria  12  NA   Cakiroglu et al,   2013  Turkey  DPN+EE  30 \u03bcg/day+3 mg/day  10  NA  Single  Rotterdam Criteria  24  NA    MET+RSV  2000 mg/day+10 mg/day  20  27.6 \u00b1 5.9  DPN+EE+MET  850 mg/day+30 \u03bcg/day+3 mg/day  9  NA     Draveck\u00e1 et al,   2016  Slovakia  ALF  1 \u03bcg/day  9  29.33 \u00b1 4.89  Single  Androgen Excess Society criteria  24  NA   Dodson et al,   1987  United States  HMG  300 IU  6  31.92  Single  NIH Criteria  4  CC    ALF+MET  1 \u03bcg/day+1700\u20132550 mg/day  11  29.2 \u00b1 5.42    MET  1700\u20132550 mg/day  12  27.6 \u00b1 4.96  HMG+LPR  300 IU + 1mg  7  31.92     De leo et al,   2010  Italy  DPN+EE  3 mg/day+30 \u03bcg/day  10  16 to 35  Single  Rotterdam Criteria  12  NA   Davar et al,   2011  Iran  CC+MET  100 mg/day+1500 mg/day  50  29.55 \u00b1 3.47  Single  Rotterdam Criteria  8  CC    CHA+EE  2 mg/day+30 \u03bcg/day  10  16 to 35    EE+GTN  75 \u03bcg/day+30 \u03bcg/day  10  16 to 35  LET+MET  5 mg/day+1500 mg/day  48  28.54 \u00b1 3.13    DGT+EE  150 \u03bcg/day+30 \u03bcg/day  10  16 to 35     Essah et al,   2011  United States  EE+MET+NRG  0.035 mg+500 mg+0.25 mg tid  10  NA  Double  Rotterdam Criteria  12  NA   Elnashar et al,   2006  Egypt  CC+DEX  100 mg/day+2 mg/day  40  23.38 \u00b1 3.5941  Double  Rotterdam Criteria  8  CC    EE+NRG+PLC  0.035 mg+0.25 mg  9  NA  CC+PLC  100 mg/day  40  25.15 \u00b1 2.3783     El-khayat et al,   2016  Egypt  CC  100 mg/day  50  26.58 \u00b1 2.93  Double  Rotterdam Criteria  24  CC   El Sharkwy et al, (a)   2019  Egypt  CC+LC+MET  150 mg/day+3 g/day+850\u20131700 mg/day  138  25.7 \u00b1 1.7  Double  Rotterdam Criteria  12  CC    LET  5 mg/day  50  25.82 \u00b1 3.62  CC+MET+PLC  150 mg/day+850\u20131700 mg/day  136  26.1 \u00b1 2.2     El Sharkwy et al, (b)   2019  Egypt  CC+NAC  150 mg/day+600 mg tid  82  26.6 \u00b1 1.5  Double  Rotterdam Criteria  12  CC   Fuxotta et al,   2010  Argentina  MET  1500 mg/day  14  25.47 \u00b1 4.82  Double  Androgen Excess Society criteria  16  NA    CC+LC  150 mg/day+3 g/day  80  26.2 \u00b1 2.8  PLC   15  24.7 \u00b1 3.46     Fruzzetti et al,   2017  Italy  MET  1500 mg/day  22  22.3 \u00b1 6.0  Single  Rotterdam Criteria  24  NA   Fr\u00f8ssing et al,   2018  Denmark  LIR  1.8 mg/day  44  NA  Double  Rotterdam Criteria  26  NA    INS 1  4 g/day  24  21.6 \u00b1 6.6  PLC   21  NA     Fleming et al,   2002  United Kingdom  MET  850 mg bid  45  28.6 (26.9\u201330.3) **  Double  NIH Criteria  14  NA   Figurov\u00e1 et al,   2017  Slovakia  MET  1700\u20132550 mg/day  12  27.6 \u00b1 4.96  Single  Androgen Excess Society criteria  24  NA    PLC   47  29.2 (27.5\u201330.7) **  ALF  1 \u03bcg/day  9  29.33 \u00b1 4.89    ALF+MET  1 \u03bcg/day+1700\u20132550 mg/day  11  29.2 \u00b1 5.42     Feng et al,   2016  China  CPA+EE+MET  2 mg/day+35 \u03bcg/day+425\u2013850 mg bid  41  27.86 \u00b1 3.79  Double  Rotterdam Criteria  12  NA   Gupta et al,   2016  United States  PGZ  45 mg/day  16  29.68 \u00b1 1.10 *  Double  NIH Criteria  24  NA    CPA+EE  2 mg/day+35 \u03bcg/day  41  28.57 \u00b1 3.04  PLC   16  30.56 \u00b1 1.08 *     Glintborg et al,   2006\u20132009  Denmark  PGZ  30 mg/day  15  32 (26\u201336) ***  Double  NIH Criteria  16  NA   Gerli et al,   2003  Italy  INS 1  100 mg bid  136  28.6 (26.9\u201330.3) **  Double  Rotterdam Criteria  1  NA    PLC   15  34 (29\u201338) ***  PLC   147  29.2 (27.5\u201330.7) **     Genazzani et al,   2008  Italy  FA+INS 1  200 \u03bcg/day+2 g/day  10  NA  Single  Rotterdam Criteria  12  NA   Gambineri et al, (24 wks)   2004\u20132006  Italy  PLC   19  26.0 \u00b1 5.0  Single  Rotterdam Criteria  24  NA    MET  850 mg bid  20  28.0 \u00b1 8.0    FA  200 \u03bcg/day  10  NA  FLT  250 mg bid  17  26.0 \u00b1 6.0    FLT+MET  250 mg bid+850 mg bid  20  26.0 \u00b1 5.0     Gambineri et al, (48 wks)   2006  Italy  PLC   19  26.0 \u00b1 5.0  Single  Rotterdam Criteria  48  NA   Gadir et al,   1991  United Kingdom  HMG  150 IU  30  26.5 \u00b1 0.73 *  Single  Rotterdam Criteria  20  CC    MET  850 mg bid  20  28.0 \u00b1 8.0    FLT  250 mg bid  17  26.0 \u00b1 6.0  FSH  75 IU  29  27.3 \u00b1 0.66 *    FLT+MET  250 mg bid+850 mg bid  20  26.0 \u00b1 5.0     Hutchison et al,   2008  Australia  MET  1000 mg bid  19  34.1  Single  NIH Criteria  24  NA   Hoeger et al, (a)   2008  United States  MET  1700 mg/day  10  16.0 \u00b1 1.7  Double  NIH Criteria  24  NA    PLC   11  15.4 \u00b1 1.7    CPA+EE  2 mg/day+35 \u03bcg/day  19  34.1    DGT+EE  0.15 mg/day+30 \u03bcg/day  11  15.4 \u00b1 1.4     Hoeger et al, (b)   2008  United States  DPN+EE+MET  3 mg/day+30 \u03bcg/day+2000 mg/day  18  14.7 \u00b1 1.6  Double  NIH Criteria  24  NA   Hanjalic-beck et al,   2010  Germany  MET  2550 mg/day  19  28.0  Double  NIH Criteria  12  NA    DPN+EE+PLC  3 mg/day+30 \u03bcg/day  18  15.8 \u00b1 1.6  ACR  300 mg/day  18  28.0     Jakubowicz et al,   2001  United States  MET  500 mg tid  26  27.0 \u00b1 1.0 *  Double  NIH Criteria  4  NA   Jamilian et al, (a)   2017  Iran  MET  500 mg tid  30  25.9\u00b14.8  Double  Rotterdam Criteria  12  NA    PLC   22  27 .0 \u00b1 1.0 *  FA+INS 1  200 \u03bcg bid+2 g bid  30  27.7\u00b15.2     Jamilian et al, (b)   2018  Iran  MET  500 mg tid  30  27.7 \u00b1 3.4  Double  Rotterdam Criteria  12  NA   Javanmanesh et al,   2016  United Kingdom  MET  500 mg tid  48  29.75 \u00b1 4.90  Double  Rotterdam Criteria  24  NA    FA+INS 1  200 \u03bcg bid+2 g bid  30  28.5 \u00b1 4.7  NAC  600 mg tid  46  28.98 \u00b1 4.42     Jensterle et al,   2008  Slovenia  MET  850 mg bid  15  23.1 \u00b1 3.7  Single  NIH criteria  24  NA   Kumar et al,   2014  India  MET  500 mg tid  30  NA  Single  Rotterdam Criteria  12  NA    RGZ  4 mg/day  11  25.0 \u00b1 4.9  ORL  120 mg bid  30  NA     Koiou et al,   2013  Greece  SBT  10 mg qd  28  25.7 \u00b1 5.9  Single  Rotterdam Criteria  24  NA   Kocak et al,   2002  Turkey  CC+MET  100 mg/day+850 mg bid  28  26.2 \u00b1 3.7  Double  NIH Criteria  8  CC    ORL  120 mg bid  22  25.7 \u00b1 5.9  CC+PLC  100 mg/day  28  27.1 \u00b1 4.5     Kj\u00f8tr\u00f8d et al,   2009  Norway  MET  2000 mg/day  17  28.9 (26.7\u201331.0) **  Double  Rotterdam Criteria  14  NA   Kilic et al,   2011  Turkey  MET  850 mg bid  24  28.7 \u00b1 3.7  Double  Rotterdam Criteria  24  NA    PLC   19  29.9 (28.1\u201331.8) **  DGT+EE  0.15 mg/day+0.03 mg/day  25  29.0 \u00b1 3.5     Khorram et al,   2006  United States  CC+MET  100 mg/day+500 mg tid  16  28.4 \u00b1 0.78 *  Single  Rotterdam Criteria  3  NA   Kebapcilar et al,   2010  Turkey  CPA+EE  2 mg/day+35 \u03bcg/day  12  23.2 \u00b1 5.1  Single  Rotterdam Criteria  12  NA    CPA+EE+MET  2 mg/day+35 \u03bcg/day+850 mg bid  12  24.9 \u00b1 4.8    CC  100 mg/day  15  28.0 \u00b1 1.1 *  MET  850 mg bid  12  24.4 \u00b1 6.2    CPA+EE+SPR  2 mg/day+35 \u03bcg/day+100 mg/day  12  23.4 \u00b1 5.8     Kebapcilar et al,   2009  Turkey  CPA+EE  2 mg/day+35 \u03bcg/day  22  24.1 \u00b1 5.6  Single  Rotterdam Criteria  12  NA   Kazerooni et al,   2010  United States  MET+SMV  500 mg tid+20 mg/day  42  25.6 \u00b1 4.32  Double  Rotterdam Criteria  12  NA    CPA+EE+MET  2 mg/day+35 \u03bcg/day+1700 mg/day  21  25.1 \u00b1 1.4  MET+PLC  500 mg tid  42  24.9 \u00b1 5.81     Kazerooni et al,   2009  United States  CC+MET  100 mg/day+500 mg tid  20  24.5 \u00b1 5.16  Double  Rotterdam Criteria  4  CC   Kaya et al,   2015  Turkey  DPN+EE  3 mg/day+3 \u03bcg/day  25  23.0 \u00b1 5.0  Double  Rotterdam Criteria  24  NA    CC+PLC  100 mg/day  20  25.47 \u00b1 4.7  DPN+EE+MET  3 mg/day+3 \u03bcg/day+850 mg bid  25  24.0 \u00b1 4.0     Kaya et al,   2012  Turkey  DPN+EE  3 mg/day+3 \u03bcg/day  19  23.2 \u00b1 5.4  Double  Androgen Excess Society criteria  24  NA   Karimzadeh et al,   2007  Iran  MET  500 mg tid  100  27.2 \u00b1 6.8  Double  Rotterdam Criteria  12  NA    DPN+EE+MET  3 mg/day+3 \u03bcg/day+850 mg bid  18  23.0 \u00b1 4.5  PLC   100  28.6 \u00b1 7.4     Ko et al,   2001    500 mg tid    Single  NIH Criteria     Lord et al,   2006  United Kingdom  MET  500 mg tid  21  27.76 \u00b1 4.89  Double  Rotterdam Criteria  12  NA        PLC   19  30.63 \u00b1 4.84     De Leo et al,   2013  Italy  INS 1 +MNK  1.5 g/day+3 g bid  20  24 to 32  Single  Rotterdam Criteria  24  NA   Lemay et al,   2006  Canada  RGZ  4 mg/day  10  26.8 \u00b1 5.7  Single  Rotterdam Criteria  24  NA    INS 1  1.5 g/day  20  24 to 32    CPA+EE  2 mg/day+35 \u03bcg/day  7  20.0 \u00b1 1.5    MET  850 mg bid  20  24 to 32     Legro et al,   2014  United States  CC  50 mg/day  376  28.8 \u00b1 4.0  Double  Rotterdam Criteria  16  NA   Legro et al,   2007  United States  CC+PLC  50 mg/day  209  27.9 \u00b1 4.0  Double  NIH criteria and Rotterdam diagnostic criteria  24  NA    MET+PLC  500 mg tid  208  28.1 \u00b1 4.0    LET  2.5 mg/day  374  28.9 \u00b1 4.5    CC+MET  50 mg/day+500 mg tid  209  28.3 \u00b1 4.0     Ladson et al,   2011  United States  MET  500 mg bid    Double  NIH Criteria  24  NA   Morin-Papunen et al,   2000  Finland  MET  1000 mg bid  16  29.9 \u00b1 1.5 *  Single  NIH Criteria  24  NA    PLC   59  28.8 \u00b1 4.6  CPA+EE  2 mg/day+35 \u03bcg/day  16  28.8 \u00b1 1.0 *     Moini et al,   2015  Iran  ORL  120 mg tid  50  26.8 \u00b1 5.16  Double  Rotterdam Criteria  12  NA   Mohsen et al,   2012  Egypt  CC+RGZ  100 mg+4 mg bid  46  25.9 \u00b1 2.7  Single  Rotterdam Criteria  12  NA    PLC   50  27.42 \u00b1 3.31  CC  100 mg/day  45  26.4 \u00b1 2.9     Mohiyideen et al,   2013  United Kingdom  RGZ  4 mg od  18  29.0 \u00b1 1.0  Double  Rotterdam Criteria  12  NA   Moghetti et al,   2000  Italy  MET  500 mg tid  12  23.9 \u00b1 1.2 *  Double  NIH Criteria  24  NA    MET  500 mg bid  17  30.0 \u00b1 0.9  PLC   11  21.4 \u00b1 1.4 *     Mehrabian et al,   2016  Iran  MET  1000 mg/day  37  29.18 \u00b1 8.288  Single  NIH Criteria  24  NA   Machado et al,   2012  Brazil  MET  850 mg bid  21  27.4 \u00b1 3.8  Double  Rotterdam Criteria  8  NA    EE+FLT+LVT  0.03 mg/day +62.5 mg/day+0.15 mg/day  37  29.0 \u00b1 7.663    PLC   15  28.2 \u00b1 3.2    SMV  20 mg/day  37  29.15 \u00b1 8.261     Nylander et al,   2017  Denmark  LIR  1.8 mg/day  48  31.4 (24.6\u201335.6) ***  Double  Rotterdam Criteria  26  NA   Nestler et al,   1999  United States  INS 2  1200 mg/day  22  29.0 \u00b1 6.0  Double  NIH Criteria  6 to 8  NA    PLC   24  26.2 (24.8\u201331.5) ***  PLC   22  26.0 \u00b1 5.0     Nestler et al,   1998  United States  MET  500 mg tid  35  29.0 \u00b1 1.0 *  Single  NIH Criteria  5  NA   Nordio et al,   2012  Italy  INS 1  550 mg bid  24  28.2 \u00b1 1.5  Single  Rotterdam Criteria  24  NA    PLC   26  28.0 \u00b1 1.0 *  INS 1 +INS 2  550 mg bid+13.8 mg bid  26  27.9 \u00b1 1.4     Onalan et al, (a)   2005  Turkey  MET  500\u2013850 mg bid  10  24.6 \u00b1 4.8  Double  NIH Criteria  24  NA   Onalan et al, (b)   2005  Turkey  MET  500\u2013850 mg bid  10  31.8 \u00b1 4.0  Double  NIH Criteria  24  NA    PLC   9  27.3 \u00b1 4.4  PLC   8  21.2 \u00b1 5.5     Pasquali et al, (4 wks)   2000  Italy  MET  850 mg bid  12  31.6 \u00b1 10.3  Double  NIH Criteria  4  NA   Pasquali et al, (28 wks)   2000  Italy  MET  850 mg bid  20  31.6 \u00b1 10.3  Double  NIH Criteria  28  NA    PLC   8  36.3 \u00b1 9.5  PLC   20  36.3 \u00b1 9.5     Parsanezhad et al, (12 wks)   2004  Iran  BRM+CC  7.5 mg/day+150 mg/day  47  25.02 \u00b1 2.7  Double  NIH Criteria  12  CC   Parsanezhad et al, (24 wks)   2004  Iran  BRM+CC  7.5 mg/day+150 mg/day  47  25.02 \u00b1 2.7  Double  NIH Criteria  24  CC    CC+PLC  150 mg/day  53  24.87 \u00b1 2.9  CC+PLC  150 mg/day  53  24.87 \u00b1 2.9     Parsanezhad et al,   2002  Iran  CC+DEX  200 mg/day+2 mg/day  20  23.56  Double  NIH Criteria  3  CC   Rautio et al, (12 wks)   2005  Finland  MET  500\u20131000 mg bid  16  29.6 \u00b1 1.1 *  Single  Rotterdam Criteria  12  NA    CC+PLC  200 mg/day  20  23.36  CPA+EE  2 mg+0.035 mg  16  29.6 \u00b1 1.1 *     Rautio et al, (24 wks)   2005  Finland  MET   16  29.6 \u00b1 1.1 *  Single  Rotterdam Criteria  24  NA   Rautio et al,   2006  Finland  RGZ  4\u20138 mg/day  15  26.7 \u00b1 1.1 *  Double  Rotterdam Criteria  16  NA    CPA+EE   16  29.6 \u00b1 1.1 *  PLC   15  30.1 \u00b1 2.1 *     Rautio et al,   2007  Finland  RGZ  4\u20138 mg/day  12  29.1 \u00b1 1.2 *  Double  Rotterdam Criteria  16  NA   Rouzi et al,   2006  Saudi Arabia  CC+RGZ  100 mg/day+4 mg bid  12  28.58 \u00b1 3.73  Single  NIH Criteria  12  CC    PLC   14  29.1 \u00b1 1.2 *  CC+MET  100 mg/day+500 mg tid  13  27.38 \u00b1 4.29     Sova et al,   2013  Finland  MET  1000 mg bid  23  29.2 \u00b1 4.6  Double  Rotterdam Criteria  12  NA   S\u00f6nmez et al,   2005  Turkey  ACR+CC  300 mg/day+100 mg/day  15  26.13 \u00b1 5.08  Double  NIH Criteria  12  CC    PLC   27  27.4 \u00b1 4.9  CC+MET  100 mg/day+1700 mg/day  15  26.0 \u00b1 3.92     Song et al,   2018  China  CPA+EE+ORL  2 mg/day+35 \u03bcg/day+120 mg tid  60  26.77 \u00b1 4.12  Double  Rotterdam Criteria  12  NA   Sathyapalan et al,   2010  United Kingdom  ATR+MET  20 mg/day+500 mg tid  19  26.6 \u00b1 1.2 *  Double  NIH Criteria  24  NA    CPA+EE+MET  2 mg/day+35 \u03bcg/day+500\u20131500 mg/day  60  28.63 \u00b1 5.12    CPA+EE+MET+ORL  2 mg/day+35 \u03bcg/day+500\u20131500 mg/day+120 mg tid  60  27.57 \u00b1 4.58  MET+PLC  500 mg tid  18  28.8 \u00b1 1.8 *    CPA+EE  2 mg/day+35 \u03bcg/day  60  27.68 \u00b1 4.99     Tfayli et al,   2011  United States  DPN+EE  3 mg/day+30 \u03bcg/day  20  16.2 \u00b1 0.3 *  Double  NIH Criteria  24  NA   Tang et al,   2006  United Kingdom  MET  850 mg bid  69  29.7 \u00b1 3.7  Double  Rotterdam Criteria  24  NA    RGZ  4 mg/day  17  15.7 \u00b1 0.3 *  PLC   74  29.8 \u00b1 3.8     Villaseca et al,   2004  Chile  MPA  10 mg/day  15  23.9 \u00b1 5.1  Single  NIH Criteria  12  NA   Vanky et al, (a)   2004  Norway  MET+PLC  850 mg tid  15  28.3 \u00b1 5.0  Double  Rotterdam Criteria  8  NA    BRM+MET  5 mg/day+850 mg tid  14  28.3 \u00b1 5.0    CPA+EE  2 mg/day+35 \u03bcg/day  16  22.4 \u00b1 6.1    DEX+MET  0.5 mg/day+850 mg tid  12  28.3 \u00b1 5.0     Vanky et al, (b) (8 wks)   2004  Norway  DEX+MET  0.5 mg/day+850 mg tid  18  26.4 \u00b1 3.8  Double  Rotterdam Criteria  8  NA   Vanky et al, (b) (26 wks)   2004  Norway  DEX+MET  0.5 mg/day+850 mg tid  18  26.4 \u00b1 3.8  Double  Rotterdam Criteria  26  NA    MET+PLC  850 mg tid  20  30.6 \u00b1 5.9  MET+PLC  850 mg tid  20  30.6 \u00b1 5.9     Vandermolen et al,   2001  United States  MET  500 mg tid  11  29.0 \u00b1 1.2 *  Double  NIH Criteria  7  CC   Van Santbrink et al,   2005  The Netherlands  MET  850 mg bid  11  28.0 (22\u201332) ****  Double  NIH Criteria  5  NA    PLC   14  30.0 \u00b1 1.0 *  PLC   9  28.0 (24\u201334) ****     Wu et al,   2008  China  CPA+EE  2 mg/day+35 \u03bcg/day  7  25.0 \u00b1 4.3  Double  Rotterdam Criteria  12  NA   Yarali et al,   2002  Turkey  MET  850 mg bid  16  29.7 \u00b1 5.6  Double  NIH Criteria  6  CC    MET  500 mg tid  7  25.6 \u00b1 3.6    PLC   16  28.4 \u00b1 5.1    CPA+EE+MET  2 mg/day+35 \u03bcg/day+500 mg tid  6  24.5 \u00b1 2.4     Yilmaz et al,   2005  Turkey  MET  850 mg bid  43  24.67 \u00b1 4.6  Single  Rotterdam Criteria  24  NA   Zheng et al,   2019  China  EXN  10 \u03bcg bid  31  27.2 \u00b1 1.76 *  Single  Rotterdam Criteria  12  NA    RGZ  4 mg/day  45  25.13 \u00b1 4.43  MET  1000 mg bid  32  27.7 \u00b1 1.64 *        INS 1 : Myo-Inositol; INS 2 : D-Chiro-Inositol    *: Mean SEM    **:Mean (Confidence intervals 95%)    ***:median (25%\u201375% quartiles)    ****: Median (Range)    Interventions: acarbose (ACR), alfacalcidol (ALF), anastrozole (ANZ), clomiphene citrate (CC), exenatide (EXN), folic acid (FA), flutamide (FLT) pure follicle-stimulating hormone (FSH), human menopausal gonadotropins (HMG), inositol (INS), letrozole (LET), liraglutide (LIR), metformin (MET), medroxyprogesterone acetate (MPA), N-acetyl cysteine (NAC), orlistat (ORL), pioglitazone (PGZ), placebo (PLC), rosiglitazone (RGZ), sibutramine (SBT), simvastatin (SMV), and troglitazone (TGZ). Acarbose+clomiphene citrate (ACR+CC), alfacalcidiol+metformin (ALF+MET), atorvastatin+metformin (ATR+MET), bromocriptine+clomiphene citrate (BRM+CC), bromocriptine+metformin (BRM+MET), clomiphene citrate+dexamethasone (CC+DEX), clomiphene citrate+ketoconazole (CC+KTZ), clomiphene citrate+l-carnitine (CC+LC), clomiphene citrate+l-carnitine+metformin (CC+LC+MET), clomiphene citrate+metformin (CC+MET), clomiphene citrate+N-acetylcysteine (CC+NAC), clomiphene citrate+rosiglitazone (CC+RGZ), chlormadinone acetate+ethinylestradiol (CHA+EE), cyproterone acetate+ethinylestradiol (CPA+EE), cyproterone acetate+ethinylestradiol+metformin (CPA+EE+MET), cyproterone acetate+ethinylestradiol+metformin+orlistat (CPA+EE+MET+ORL), cyproterone acetate+ethinylestradiol+orlistat (CPA+EE+ORL), cyproterone acetate+ethinylestradiol+spironolactone (CPA+EE+SPR), dexamethasone+metformin (DEX+MET), desogestrel+ethinylestradiol (DGT+EE), drospirenone+ethinylestradiol (DPN+EE), drospirenone+ethinylestradiol+metformin (DPN+EE+MET), ethinylestradiol+flutamide+levonorgestrel (EE+FLT+LVT), ethinylestradiol+gestodene (EE+GTN), ethinylestradiol+metformin+norgestimate (EE+MET+NRG), ethinylestradiol+norgestimate (EE+NRG), folic acid+inositol (FA+INS), flutamide+metformin (FLT+MET), human menopausal gonadotropins+ leuprolide (HMG+LPR), inositol+monacolin k (INS+MNK), letrozole+metformin (LET+MET), metformin+rosuvastatin (MET+RSV), and metformin+simvastatin (MET+SMV).     All of the included studies were randomized, blinded, and were treated as an intention to treat (ITT) analysis; thus, exhibiting a low risk of bias. The funnel plot was visually symmetrical ( S1 File ; S1 Fig in S1 File ), indicating no possible publication bias, and the further Egger\u2019s test revealed no small study effect (P = 0.35). The overall quality of evidence for each outcome in this network meta-analysis was evaluated according to the CINeMA framework, revealing high-quality evidence ( S3 File\u2014CINeMA ). Overall, 692 direct comparisons and 7,166 indirect comparisons were obtained for the 17 outcomes from 101 trials.    3.2 Pairwise meta-analyses  We performed a pairwise meta-analysis for RCTs that compared the same interventions employing the random-effects IVhet model. The results of these analyses are displayed in S4 File\u2014Pairwise plots. No statistically significant difference was observed among interventions regarding WHR (I^2 = 0%, P = 0.986), FSH (I^2 = 0%, P = 1.000), Estradiol (I^2 = 0%, P = 1.000), FGS (I^2 = 0%, P = 0.991), Free Testosterone (I^2 = 0%, P = 1.000), and HDL (I^2 = 0%, P = 0.896). Pooled analyses were homogenous  For BMI, only the following comparisons revealed significance: CPA+EE+MET+ORL# vs. CPA+EE# (MD = \u22123.2, 95% CI [\u22126.3, \u22120.1]), CPA+EE+MET+ORL# vs. CPA+EE+ORL# (MD = \u22125, 95% CI [\u22128.4, \u22121.6]), FLT vs. MET (MD = \u22124, 95% CI [\u22126.6, \u22121.3]), FLT vs. PLC (MD = \u22124.95, 95% CI [\u22127.6, \u22122.2]), and FLT+MET vs. PLC (MD = \u22123.4, 95% CI [\u22126.3, \u22120.6]). Pooled analysis was homogenous (I^2 = 34.29%, P = 0.013).  For LH (mIU/ml) , only the following comparisons revealed significance: MET vs. PLC (MD = \u22124.5, 95% CI [\u22128.3, \u22120.8]). LIR was inferior to PLC in reducing LH levels (MD = 23.9, 95% CI [18.2, 29.5]). Pooled analysis was moderately heterogeneous (I^2 = 65.27%, P< 0.001), and heterogeneity did not resolve after further sensitivity analysis.  For SHBG (nmol/L) , only the following comparisons revealed significance: CPA+EE vs. MET (MD = 113.7, 95% CI [84.5, 142.9]), CPA+EE vs. RGZ (MD = 89, 95% CI [ 51 , 127 ]), DGT+EE vs. PLC (MD = 103, 95% CI [65.6, 140.3]), DPN+EE vs. DGT+EE (MD = 33.2, 95% CI [3.3, 63.1]), DPN+EE vs. RGZ (MD = 97, 95% CI [60.4, 133.5]), and INS+MNK vs. INS (MD = 46, 95% CI [1.42, 90.5]). Pooled analysis was moderately heterogeneous (I^2 = 76.33%, P< 0.001), and heterogeneity did not resolve after further sensitivity analysis.  For Total Testosterone (ng/dl) , only the following comparisons revealed significance: CPA+EE vs. MET (MD = \u221221.3, 95% CI [\u221240.1, \u22122.4]), DGT+EE vs. MET (MD = \u221229, 95% CI [\u221252.5, \u22125.4]), DGT+EE vs. PLC (MD = \u221230.6, 95% CI [\u221255.8, \u22125.4]), and CC+DEX# vs. PLC (MD = \u221251, 95% CI [\u221293.5, \u22128.4]). Pooled analysis was homogenous (I^2 = 0%, P = 0.541).  For DHEAS (\u03bcg/dl) , only the following comparisons revealed significance: FLT vs. MET (MD = \u221274.6, 95% CI [\u2212127.7, \u221221.4]), FLT vs. PLC (MD = \u221269.8, 95% CI [\u2212125, \u221214.7]), INS# vs. PLC (MD = \u2212147, 95% CI [\u2212255.6, \u221238.3]), and MET+RSV# vs. MET# (MD = \u2212121.3, 95% CI [\u2212237.3, \u22125.2]). Pooled analysis was homogenous (I^2 = 22.23%, P = 0.104).  For Total Cholesterol (mg/dl) , only the following comparisons revealed significance: MET+SMV# vs. MET# (MD = \u221253.2, 95% CI [\u221297.1, \u22129.4]). Pooled analysis was homogenous (I^2 = 0%, P = 0.991).  For LDL (mg/dl) , only the following comparisons revealed significance: INS+MNK vs. INS (MD = \u221277.9, 95% CI [\u2212103.5, \u221252.2]), INS+MNK vs. MET (MD = \u221271, 95% CI [\u221292.6, \u221249.3]), MET vs. DGT+EE (MD = \u221230.3, 95% CI [\u221259.4, \u22121.2]), MET# vs. PLC (MD = \u221210.3, 95% CI [\u221218.4, \u22122.3]), MET+SMV# vs. MET# (MD = \u221221, 95% CI [\u22120.8, \u221241.2]), and ORL# vs. PLC (MD = \u221228.4, 95% CI [\u221244.6, \u221212.2]). Pooled analysis was moderately heterogeneous (I^2 = 70.17%, P< 0.001), and heterogeneity did not resolve after further sensitivity analysis.  For Triglycerides (mg/dl) , only the following comparisons revealed significance: FLT vs. MET (MD = \u221227.5, 95% CI [\u221253.1, \u22121.9]), FLT vs. PLC (MD = \u221232.7, 95% CI [\u22126.5, \u221258.9]), and MET+RSV# vs. MET# (MD = \u221241.5, 95% CI [\u221277.6, \u22125.3]). DPN+EE was inferior to RGZ in reducing Triglycerides levels (MD = 84.2, 95% CI [51.4, 117.1]). Pooled analysis was homogenous (I^2 = 39.13%, P = 0.003).  For Fasting Glucose (mg/dl) , only the following comparisons revealed significance: MET# vs. PLC (MD = \u22125.4, 95% CI [\u221210.1, \u22120.7]), and MET# vs. ORL# (MD = \u221221.6, 95% CI [\u221233.3, \u22129.9]. ORL# was inferior to PLC in reducing Fasting Glucose levels (MD = 16.1, 95% CI [4.8, 27.5]). Pooled analysis was homogenous (I^2 = 0%, P = 0.698).  For Fasting Insulin (pmol/L) , only the following comparisons revealed significance: CC+MET vs. CC (MD = \u2212279.1, 95% CI [\u2212352.9, \u2212205.4]), and MET vs. CC (MD = \u2212250.7, 95% CI [\u2212324.4, \u2212176.9]). CPA+EE and DPN+EE were inferior to RGZ in reducing Fasting Insulin levels (MD = 63.648, 95% CI [4.4, 122.8]) and (MD = 62.6, 95% CI [5.7, 119.5]); respectively. Pooled analysis was moderately heterogeneous (I^2 = 61.7%, P< 0.001), and heterogeneity did not resolve after further sensitivity analysis.  For HOMA-IR, only the following comparisons revealed significance: ALF vs. ALF+MET (MD = \u22121.1, 95% CI [\u22122.2, \u22120.04]), CC+MET vs. CC (MD = \u22121.9, 95% CI [\u22122.7, \u22121]), CPA+EE+MET# vs. CPA+EE# (MD = \u22120.6, 95% CI [\u22121.1, \u22120.09]), DGT+EE vs. CPA+EE (MD = \u22121.1, 95% CI [\u22121.7, \u22120.4]), DGT+EE vs. DPN+EE (MD = \u22121.1, 95% CI [\u22121.7, \u22120.5]), MET vs. ALF+MET (MD = \u22121.9, 95% CI [\u22123, \u22120.9]), MET vs. CC (MD = \u22121.1, 95% CI [\u22121.9, \u22120.2]), MET vs. CPA+EE (MD = \u22121.3, 95% CI [\u22122.5, \u22120.2]), PGZ vs. PLC (MD = \u22122.1, 95% CI [\u22123, \u22121.1]), and RGZ vs. CPA+EE (MD = \u22121.4, 95% CI [\u22122.7, \u22120.1]). Pooled analysis was moderately heterogeneous (I^2 = 68.32%, P< 0.001), and heterogeneity did not resolve after further sensitivity analysis.    3.3 Network meta-analyses  Additionally, we performed a frequentist network meta-analysis. Following the results of node-splitting analyses, we adopted the consistency model. The estimated value of between-study variance in the network ranged from 2.2 to 309.7. Among indirect comparisons, significant inconsistencies were identified in the closed-loop of MET#-ORL#-PLC and DGT+EE-DPN+EE-MET-RGZ ( S1 File ; S2 Fig in S1 File ). Further, employing the Global test based on the random-effects design-by-treatment interaction model, \u03c72 values ranged from 0.1 (1 df.) to 10.6 (12 df.), P-value: 0.2\u20130.5; respectively. Moreover, comparisons with significant heterogeneity or incoherence were downgraded ( S3 File\u2014CINeMA ).  Results of each direct and indirect comparison in the network meta-analysis are detailed extensively in S2 File\u2014NMA League Tables. In addition to the significant estimates of the pairwise meta-analysis, the following comparisons revealed a statistical significance as well. Compared with placebo, MET+RSV# and CPA+EE+SPR# were superior at reducing LDL levels (MD = -29.1, 95% CI [-51.9, -93.7]) and (MD = -25.3, 95% CI [-48.2, -2.5]); respectively, DPN+EE+MET was inferior at reducing Triglycerides levels (MD = 83.6, 95% CI [16.8, 150.4]), and CC was inferior at reducing Fasting Insulin levels (MD = 254.9, 95% CI [176.4, 333.4]) ( Fig 3 ).   10.1371/journal.pone.0254412.g003  Fig 3   Forest plots show the mean difference (MD) of different interventions compared with placebo for each outcome, along with the associated 95% CI.  Interventions: acarbose (ACR), alfacalcidol (ALF), anastrozole (ANZ), clomiphene citrate (CC), exenatide (EXN), folic acid (FA), flutamide (FLT) pure follicle-stimulating hormone (FSH), human menopausal gonadotropins (HMG), inositol (INS), letrozole (LET), liraglutide (LIR), metformin (MET), medroxyprogesterone acetate (MPA), N-acetyl cysteine (NAC), orlistat (ORL), pioglitazone (PGZ), placebo (PLC), rosiglitazone (RGZ), sibutramine (SBT), simvastatin (SMV), and troglitazone (TGZ). Acarbose+clomiphene citrate (ACR+CC), alfacalcidiol+metformin (ALF+MET), atorvastatin+metformin (ATR+MET), bromocriptine+clomiphene citrate (BRM+CC), bromocriptine+metformin (BRM+MET), clomiphene citrate+dexamethasone (CC+DEX), clomiphene citrate+ketoconazole (CC+KTZ), clomiphene citrate+l-carnitine (CC+LC), clomiphene citrate+l-carnitine+metformin (CC+LC+MET), clomiphene citrate+metformin (CC+MET), clomiphene citrate+N-acetylcysteine (CC+NAC), clomiphene citrate+rosiglitazone (CC+RGZ), chlormadinone acetate+ethinylestradiol (CHA+EE), cyproterone acetate+ethinylestradiol (CPA+EE), cyproterone acetate+ethinylestradiol+metformin (CPA+EE+MET), cyproterone acetate+ethinylestradiol+metformin+orlistat (CPA+EE+MET+ORL), cyproterone acetate+ethinylestradiol+orlistat (CPA+EE+ORL), cyproterone acetate+ethinylestradiol+spironolactone (CPA+EE+SPR), dexamethasone+metformin (DEX+MET), desogestrel+ethinylestradiol (DGT+EE), drospirenone+ethinylestradiol (DPN+EE), drospirenone+ethinylestradiol+metformin (DPN+EE+MET), ethinylestradiol+flutamide+levonorgestrel (EE+FLT+LVT), ethinylestradiol+gestodene (EE+GTN), ethinylestradiol+metformin+norgestimate (EE+MET+NRG), ethinylestradiol+norgestimate (EE+NRG), folic acid+inositol (FA+INS), flutamide+metformin (FLT+MET), human menopausal gonadotropins+ leuprolide (HMG+LPR), inositol+monacolin k (INS+MNK), letrozole+metformin (LET+MET), metformin+rosuvastatin (MET+RSV), and metformin+simvastatin (MET+SMV).     The ranking probabilities of the highest and lowest intervention for each outcome are available in S1 File ; S3 Fig in S1 File . The two-dimensional cluster ranking of the average SUCRA values for metabolic and hormonal parameters with significant estimates revealed FLT (77.5%, 70%; respectively) as the highest and RGZ# (38.2%, 26.3%; respectively) as the lowest, in terms of the overall efficacy. However, CPA+EE exhibited a higher ranking in improving hormonal parameters (71.1%), but even a lower-ranking regarding metabolic parameters (34.5%) ( Fig 4 ).   10.1371/journal.pone.0254412.g004  Fig 4   A rankogram show the cumulative ranking of the average SUCRA values for each intervention across all metabolic and hormonal parameters.       3.4 Meta-regressions  We further employed multiple regression models to assess the interaction between anthropometric, metabolic, and hormonal parameters with significant estimates. The results of these meta-regressions are available in S1 File ; S4 Fig in S1 File . Changes in BMI were significantly associated with changes in SHBG (Coefficient 0.012; P = 0.000, R2 = 51.6%), Total Testosterone (Coefficient -0.031; P = 0.000, R2 = 34%), and DHEAS (Coefficient 0.004; P = 0.02, R2 = 8%). The inversed regression for the effect of BMI on these parameters had a lower R2 value for SHBG (2.62%) Total Testosterone (0%), and DHEAS (0%).  In contrast, LDL and Triglyceride levels showed no significant associations with Total Testosterone (P = 0.86, P = 0.54; respectively) or DHEAS levels (P = 0.31, P = 0.76; respectively). However, changes in LDL and Triglyceride levels were significantly associated with changes in SHBG (Coefficient 0.012; P = 0.001, R2 = 7.8%) and (Coefficient 0.225; P = 0.000, R2 = 16.4%); respectively. The inversed regression for the effect of LDL and Triglycerides on SHBG was not significant (P = 0.43, P = 0.53; respectively). Likewise, no significant associations were detected between HOMA-IR and either SHBG (P = 0.9) or Total Testosterone (P = 0.95) or DHEAS (P = 0.97).     4. Discussion  In the present systematic review and network meta-analysis: 55 interventions were evaluated for efficacy in reducing weight and hyperandrogenism through 7,858 comparisons across 17 outcomes. The included interventions can be categorized pharmacologically into ten categories: Oral contraceptives, Gonadotropins modulators, Estrogen modulators, Aromatase inhibitors, Catecholamines modulators, Antiandrogens, Antidiabetics, Cholesterol modulators, Antioxidants, and Anti-inflammatories. After a long chain of analyses, the competition settled between Antiandrogens, Oral contraceptives, Anti-diabetics, Cholesterol modulators, and combinations in-between categories.  Flutamide, an antiandrogen, proved efficacy in improving anthropometric, androgenic, and lipid parameters. Cyproterone acetate+ethinylestradiol, an antiandrogen with an oral contraceptive, demonstrated the highest efficacy in improving androgenic parameters. However, it did not exhibit any superiority in the remaining parameters. Inositol+monacolin K, an antidiabetic and a cholesterol modulator, displayed efficacy in improving androgenic and lipid parameters. Likewise, metformin+simvastatin/rosuvastatin and orlistat, an antidiabetic and cholesterol modulators, significantly improved lipid parameters. Nonetheless, these improvements were only observable in the short term follow-up.  Ideally, all interventions were comparable in female hormones, FGS, HDL, glucose, and insulin levels improvements. As an exception, liraglutide, an antidiabetic, showed a significantly lower efficacy in reducing LH levels. Clomiphene citrate, an estrogen modulator, was the least effective agent in improving insulin levels. Eventually, pioglitazone, an antidiabetic, demonstrated efficacy in reducing HOMA-IR.  Meanwhile, results of meta-regression revealed no significant associations between changes in hormonal and metabolic parameters. Even those few significant associations had a very small R-squared. This finding indicates that a drug\u2019s action on hormonal parameters does not necessarily modify metabolic parameters and vice versa. Also, this finding is counter-intuitive to previous studies that attributed PCOS progression to lipid metabolism disturbance [ 137 , 138 ]. This implication may provide further justification for the combined therapies of different categories. However, our analysis revealed that most combinations were not promising. For instance, the combinations of flutamide+metformin, ethinylestradiol+flutamide+levonorgestrel, cyproterone acetate+ethinylestradiol+metformin, and cyproterone acetate+ethinylestradiol+orlistat were inferior to either agent separately. Still, it remains questionable whether a future combination of flutamide+cyproterone acetate+ethinylestradiol can create better potentials.  On the other hand, meta-regression revealed a significant effect of hormonal parameters on anthropometric parameters. This finding could explain why traditional obesity interventions show limited efficacy and limited duration in obese PCOS patients [ 139 , 140 ]. Further, it implies that: when treating PCOS obesity, physicians should consider interventions with hormonal adjustments such as flutamide.  Given the high prevalence of obesity among PCOS patients, effective treatments that improve both obesity and reproductive functions are urgently needed [ 141 , 142 ]. Evidence indicates that PCOS patients with overweight/obesity show a higher risk of long-term morbidity including anovulation, diabetes, and cardiovascular disorders. The cumulative ranking of flutamide as the best intervention across outcomes has many implications [ 143 , 144 ].  Flutamide works by inhibiting androgen uptake or nuclear binding in the target tissues [ 145 ]. However, it has extensive metabolism, leaving only 2.5% of its concentration in plasma one hour after intake [ 146 ]. This critical issue generates an urgent need for a modified preparation. Otherwise, the ultimate current solution is multiple fractionated doses, which raises concerns about cost-effectiveness. It is important to point out that the best and worst treatment can potentially alternate according to clinical judgments. For instance, most PCOS patients are diagnosed because of irregular menstruation or infertility; however, an additional presentation with obesity, insulin resistance, hirsutism, and acne requires further consideration. Patients\u2019 value of whether they desire pregnancy or not changes the main course of management.  The mainstream literature approaches PCOS either as a mere metabolic disturbance or a fertility challenge [ 147 \u2013 150 ]. Furthermore, meta-analyses are highly selective to certain outcomes of interest as ovulation, pregnancy, metabolic syndrome, and weight loss. These attitudes, for sure, serves the value of many patients but simultaneously ignores the value of another considerable group of patients. Those patients may not be interested in pregnancy nor having serious weight problems; rather, they want their body to function with normal feminine biology for their sexual, social, and psychological lives. Likewise, previous network meta-analyses included a limited number of outcomes and interventions of particular categories and either presented no significant results or a low to very low evidence. These limitations mainly due to the inclusion of poorly designed RCTs, the limited outcomes, the limited comparisons, the incomprehensive literature search, the inclusion of post hoc analyses, and the unreliable statistical combinations.  In our systematic review and network meta-analysis: we assessed multi-dimensional outcomes, developed strict inclusion criteria, separated short-term from long term comparisons, and analyzed only well-designed RCTs in the past 30 years. Our findings settle a group of assumptions and advocate a reliable reference for future clinical decisions and guidelines. To the best of our knowledge: this is the first meta-analysis to investigate this size of outcomes with this number of interventions in the management of PCOS. The findings for various treatments involved were consistent for all measured outcomes, and the evidence presented was highly rated.  Even so, some limitations can be identified in our work: most RCTs had relatively small sample sizes; thus, the wide 95% CI of most comparisons indicates insufficient power. Also, we restricted the average BMI to over 25; hence, the implications can only apply to overweight/obese PCOS patients. The modifications in the clinical definitions and diagnostic criteria of PCOS may contribute to the clinical heterogeneity.  Overall, the current evidence demonstrated the superiority of flutamide in improving both metabolic and hormonal parameters. And the higher efficacy of cyproterone acetate+ethinylestradiol only in improving hormonal parameters. Nearly all interventions were comparable in female hormones, FGS, HDL, glucose, and insulin levels improvements. Even though inositol+monacolin K, metformin+simvastatin/rosuvastatin, and orlistat ranked higher in improving lipid parameters, their efficacy lasted only for short-term follow-ups. Liraglutide exhibited the lowest efficacy in reducing LH levels, and clomiphene citrate was the least effective agent in improving insulin levels. Pioglitazone demonstrated the highest efficacy in reducing HOMA-IR on the long-term follow-up. In the management of PCOS: a drug\u2019s action on hormonal parameters does not necessarily modify metabolic parameters and vice versa. Obesity in PCOS is a unique case of obesity that should not be merely addressed by traditional weight-loss interventions. Prospective large-scale clinical trials are crucially required to study the appropriate dosage of flutamide and to assess the efficacy of combined flutamide+cyproterone acetate+ethinylestradiol.    Supporting information   S1 File   (DOCX)     Click here for additional data file.      S2 File   Displays extended NMA League Tables.  (XLSX)     Click here for additional data file.      S3 File   Contains CINeMA frameworks for each outcome.  (XLSX)     Click here for additional data file.      S4 File   Shows the forest plots of the pairwise meta-analyses.  (PDF)     Click here for additional data file.      S5 File   Contains the detailed search terms for each database.  (DOCX)     Click here for additional data file.      S6 File   The NMA PRISMA Checklist.  (DOCX)     Click here for additional data file.",
    "tables": [
        {
            "title": "Shows baseline and summary data of patients in included studies.",
            "content": "Author  Year  Country  Groups  Dosage  Sample Size  Age  Blinding  Diagnostic Criteria  Folllow Up (Weeks)  Resistance  Author  Year  Country  Groups  Dosage  Sample Size  Age  Blinding  Diagnostic Criteria  Folllow Up (Weeks)  Resistance    Mean \u00b1 SD (years)  Mean \u00b1 SD (years)       Azziz et al,   2003  United States  PLC   73  29.3 \u00b1 5.6  Double  NIH Criteria  20  NA   Azziz et al,   2001  United States  PLC   73  30.1 \u00b1 6.0  Double  NIH Criteria  44  NA    TGZ  150 mg/day  78  29.3 \u00b1 5.6  TGZ  150 mg/day  78  28.9 \u00b1 5.4    TGZ  300 mg/day  77  29.3 \u00b1 5.6  TGZ  300 mg/day  77  29.2 \u00b1 5.8    TGZ  600 mg/day  77  29.3 \u00b1 5.6  TGZ  600 mg/day  78  29.0 \u00b1 5.2     Aroda et al,   2009  United States  PLC   10  27.0 \u00b1 1.0 *  Single  NIH Criteria  24  NA   Hassan et al, (a)   2001  Egypt  CC+KTZ  100 mg/day+400 mg/day  25  NA  Single  NIH Criteria  36  NA    PGZ  45 mg/day  13  28.0 \u00b1 1.0 *  CC  100 mg/day  38  NA     Hassan et al, (b)   2001  Egypt  CC+KTZ  100 mg/day+400 mg/day  12  NA  Single  NIH Criteria  36  CC   Abu Hashim et al,   2010  Egypt  LET  2.5 mg/day  123  28.3 \u00b1 2.7  Single  Rotterdam Criteria  8  CC    CC  100 mg/day  5  NA  CC+MET  150 mg/day+500 mg tid  127  26.2 \u00b1 2.2     Bridger et al,   2006  Canada  MET  750 mg bid  11  16.07 \u00b1 0.97  Double  NIH Criteria  12  NA   Brettenthaler et al,   2004  United Kingdom  PGZ  30 mg/day  17  30.2 \u00b1 1.4 *  Double  NIH Criteria  12  NA    PLC   11  16.08 \u00b1 1.39  PLC   18  30.6 \u00b1 1.1 *     Bilgir et al,   2009  Turkey  CPA+EE  2 mg/day+35 \u03bcg/day  20  24.3 \u00b1 5.7  Single  Rotterdam Criteria  12  NA   Bhattacharya et al, (24 wks)   2012  India  DGT+EE  0.15 mg/day+0.03 mg/day  58  22.24 \u00b1 4.47  Double  Androgen Excess Society criteria  24  NA    CPA+EE  2 mg/day+0.03 mg/day  56  22.32 \u00b1 4.17    CPA+EE+MET  2 mg/day+35 \u03bcg/day+1700 mg/day  20  25.2 \u00b1 4.6  DPN+EE  3 mg/day+0.03 mg/day  57  22.33 \u00b1 4.76     Bhattacharya et al, (48 wks)   2012  India  DGT+EE  0.15 mg/day+0.03 mg/day  58  22.24 \u00b1 4.47  Double  Androgen Excess Society criteria  48  NA   Benelli et al,   2016  Italy  FA+INS 1 + INS 2  200 \u03bcg bid+550 mg bid+13.8 mg bid  21  23 \u00b1 6.8  Single  Rotterdam Criteria  24  NA    CPA+EE  2 mg/day+0.03 mg/day  56  22.32 \u00b1 4.17    DPN+EE  3 mg/day+0.03 mg/day  57  22.33 \u00b1 4.76  FA  200 \u03bcg bid  25  25 \u00b1 7.3     Badawy et al, (a)   2009  Egypt  ANZ  1 mg/day  115  23.8 \u00b1 3.1 *  Single  Rotterdam Criteria  10  NA   Badawy et al, (b)   2009  Egypt  LET  5 mg/day  218  27.1 \u00b1 3.2 *  Single  Rotterdam Criteria  10  NA    CC  100 mg/day  101  25.3 \u00b1 2.9 *  CC  100 mg/day  220  29.3 \u00b1 2.9 *     Badawy et al,   2008  Egypt  CC  100 mg/day  160  24.1 \u00b1 3.1 *  Single  Rotterdam Criteria  16  CC   Chou et al,   2003  Brazil  MET  500 mg tid  14  24 \u00b1 5  Double  NIH Criteria  12  NA    HMG  75 IU/day  158  26.3 \u00b1 3.0 *  PLC   16  24.5 \u00b1 6.1     Celik et al,   2012  Turkey  MET  2000 mg/day  20  25.9 \u00b1 5.7  Single  Rotterdam Criteria  12  NA   Cakiroglu et al,   2013  Turkey  DPN+EE  30 \u03bcg/day+3 mg/day  10  NA  Single  Rotterdam Criteria  24  NA    MET+RSV  2000 mg/day+10 mg/day  20  27.6 \u00b1 5.9  DPN+EE+MET  850 mg/day+30 \u03bcg/day+3 mg/day  9  NA     Draveck\u00e1 et al,   2016  Slovakia  ALF  1 \u03bcg/day  9  29.33 \u00b1 4.89  Single  Androgen Excess Society criteria  24  NA   Dodson et al,   1987  United States  HMG  300 IU  6  31.92  Single  NIH Criteria  4  CC    ALF+MET  1 \u03bcg/day+1700\u20132550 mg/day  11  29.2 \u00b1 5.42    MET  1700\u20132550 mg/day  12  27.6 \u00b1 4.96  HMG+LPR  300 IU + 1mg  7  31.92     De leo et al,   2010  Italy  DPN+EE  3 mg/day+30 \u03bcg/day  10  16 to 35  Single  Rotterdam Criteria  12  NA   Davar et al,   2011  Iran  CC+MET  100 mg/day+1500 mg/day  50  29.55 \u00b1 3.47  Single  Rotterdam Criteria  8  CC    CHA+EE  2 mg/day+30 \u03bcg/day  10  16 to 35    EE+GTN  75 \u03bcg/day+30 \u03bcg/day  10  16 to 35  LET+MET  5 mg/day+1500 mg/day  48  28.54 \u00b1 3.13    DGT+EE  150 \u03bcg/day+30 \u03bcg/day  10  16 to 35     Essah et al,   2011  United States  EE+MET+NRG  0.035 mg+500 mg+0.25 mg tid  10  NA  Double  Rotterdam Criteria  12  NA   Elnashar et al,   2006  Egypt  CC+DEX  100 mg/day+2 mg/day  40  23.38 \u00b1 3.5941  Double  Rotterdam Criteria  8  CC    EE+NRG+PLC  0.035 mg+0.25 mg  9  NA  CC+PLC  100 mg/day  40  25.15 \u00b1 2.3783     El-khayat et al,   2016  Egypt  CC  100 mg/day  50  26.58 \u00b1 2.93  Double  Rotterdam Criteria  24  CC   El Sharkwy et al, (a)   2019  Egypt  CC+LC+MET  150 mg/day+3 g/day+850\u20131700 mg/day  138  25.7 \u00b1 1.7  Double  Rotterdam Criteria  12  CC    LET  5 mg/day  50  25.82 \u00b1 3.62  CC+MET+PLC  150 mg/day+850\u20131700 mg/day  136  26.1 \u00b1 2.2     El Sharkwy et al, (b)   2019  Egypt  CC+NAC  150 mg/day+600 mg tid  82  26.6 \u00b1 1.5  Double  Rotterdam Criteria  12  CC   Fuxotta et al,   2010  Argentina  MET  1500 mg/day  14  25.47 \u00b1 4.82  Double  Androgen Excess Society criteria  16  NA    CC+LC  150 mg/day+3 g/day  80  26.2 \u00b1 2.8  PLC   15  24.7 \u00b1 3.46     Fruzzetti et al,   2017  Italy  MET  1500 mg/day  22  22.3 \u00b1 6.0  Single  Rotterdam Criteria  24  NA   Fr\u00f8ssing et al,   2018  Denmark  LIR  1.8 mg/day  44  NA  Double  Rotterdam Criteria  26  NA    INS 1  4 g/day  24  21.6 \u00b1 6.6  PLC   21  NA     Fleming et al,   2002  United Kingdom  MET  850 mg bid  45  28.6 (26.9\u201330.3) **  Double  NIH Criteria  14  NA   Figurov\u00e1 et al,   2017  Slovakia  MET  1700\u20132550 mg/day  12  27.6 \u00b1 4.96  Single  Androgen Excess Society criteria  24  NA    PLC   47  29.2 (27.5\u201330.7) **  ALF  1 \u03bcg/day  9  29.33 \u00b1 4.89    ALF+MET  1 \u03bcg/day+1700\u20132550 mg/day  11  29.2 \u00b1 5.42     Feng et al,   2016  China  CPA+EE+MET  2 mg/day+35 \u03bcg/day+425\u2013850 mg bid  41  27.86 \u00b1 3.79  Double  Rotterdam Criteria  12  NA   Gupta et al,   2016  United States  PGZ  45 mg/day  16  29.68 \u00b1 1.10 *  Double  NIH Criteria  24  NA    CPA+EE  2 mg/day+35 \u03bcg/day  41  28.57 \u00b1 3.04  PLC   16  30.56 \u00b1 1.08 *     Glintborg et al,   2006\u20132009  Denmark  PGZ  30 mg/day  15  32 (26\u201336) ***  Double  NIH Criteria  16  NA   Gerli et al,   2003  Italy  INS 1  100 mg bid  136  28.6 (26.9\u201330.3) **  Double  Rotterdam Criteria  1  NA    PLC   15  34 (29\u201338) ***  PLC   147  29.2 (27.5\u201330.7) **     Genazzani et al,   2008  Italy  FA+INS 1  200 \u03bcg/day+2 g/day  10  NA  Single  Rotterdam Criteria  12  NA   Gambineri et al, (24 wks)   2004\u20132006  Italy  PLC   19  26.0 \u00b1 5.0  Single  Rotterdam Criteria  24  NA    MET  850 mg bid  20  28.0 \u00b1 8.0    FA  200 \u03bcg/day  10  NA  FLT  250 mg bid  17  26.0 \u00b1 6.0    FLT+MET  250 mg bid+850 mg bid  20  26.0 \u00b1 5.0     Gambineri et al, (48 wks)   2006  Italy  PLC   19  26.0 \u00b1 5.0  Single  Rotterdam Criteria  48  NA   Gadir et al,   1991  United Kingdom  HMG  150 IU  30  26.5 \u00b1 0.73 *  Single  Rotterdam Criteria  20  CC    MET  850 mg bid  20  28.0 \u00b1 8.0    FLT  250 mg bid  17  26.0 \u00b1 6.0  FSH  75 IU  29  27.3 \u00b1 0.66 *    FLT+MET  250 mg bid+850 mg bid  20  26.0 \u00b1 5.0     Hutchison et al,   2008  Australia  MET  1000 mg bid  19  34.1  Single  NIH Criteria  24  NA   Hoeger et al, (a)   2008  United States  MET  1700 mg/day  10  16.0 \u00b1 1.7  Double  NIH Criteria  24  NA    PLC   11  15.4 \u00b1 1.7    CPA+EE  2 mg/day+35 \u03bcg/day  19  34.1    DGT+EE  0.15 mg/day+30 \u03bcg/day  11  15.4 \u00b1 1.4     Hoeger et al, (b)   2008  United States  DPN+EE+MET  3 mg/day+30 \u03bcg/day+2000 mg/day  18  14.7 \u00b1 1.6  Double  NIH Criteria  24  NA   Hanjalic-beck et al,   2010  Germany  MET  2550 mg/day  19  28.0  Double  NIH Criteria  12  NA    DPN+EE+PLC  3 mg/day+30 \u03bcg/day  18  15.8 \u00b1 1.6  ACR  300 mg/day  18  28.0     Jakubowicz et al,   2001  United States  MET  500 mg tid  26  27.0 \u00b1 1.0 *  Double  NIH Criteria  4  NA   Jamilian et al, (a)   2017  Iran  MET  500 mg tid  30  25.9\u00b14.8  Double  Rotterdam Criteria  12  NA    PLC   22  27 .0 \u00b1 1.0 *  FA+INS 1  200 \u03bcg bid+2 g bid  30  27.7\u00b15.2     Jamilian et al, (b)   2018  Iran  MET  500 mg tid  30  27.7 \u00b1 3.4  Double  Rotterdam Criteria  12  NA   Javanmanesh et al,   2016  United Kingdom  MET  500 mg tid  48  29.75 \u00b1 4.90  Double  Rotterdam Criteria  24  NA    FA+INS 1  200 \u03bcg bid+2 g bid  30  28.5 \u00b1 4.7  NAC  600 mg tid  46  28.98 \u00b1 4.42     Jensterle et al,   2008  Slovenia  MET  850 mg bid  15  23.1 \u00b1 3.7  Single  NIH criteria  24  NA   Kumar et al,   2014  India  MET  500 mg tid  30  NA  Single  Rotterdam Criteria  12  NA    RGZ  4 mg/day  11  25.0 \u00b1 4.9  ORL  120 mg bid  30  NA     Koiou et al,   2013  Greece  SBT  10 mg qd  28  25.7 \u00b1 5.9  Single  Rotterdam Criteria  24  NA   Kocak et al,   2002  Turkey  CC+MET  100 mg/day+850 mg bid  28  26.2 \u00b1 3.7  Double  NIH Criteria  8  CC    ORL  120 mg bid  22  25.7 \u00b1 5.9  CC+PLC  100 mg/day  28  27.1 \u00b1 4.5     Kj\u00f8tr\u00f8d et al,   2009  Norway  MET  2000 mg/day  17  28.9 (26.7\u201331.0) **  Double  Rotterdam Criteria  14  NA   Kilic et al,   2011  Turkey  MET  850 mg bid  24  28.7 \u00b1 3.7  Double  Rotterdam Criteria  24  NA    PLC   19  29.9 (28.1\u201331.8) **  DGT+EE  0.15 mg/day+0.03 mg/day  25  29.0 \u00b1 3.5     Khorram et al,   2006  United States  CC+MET  100 mg/day+500 mg tid  16  28.4 \u00b1 0.78 *  Single  Rotterdam Criteria  3  NA   Kebapcilar et al,   2010  Turkey  CPA+EE  2 mg/day+35 \u03bcg/day  12  23.2 \u00b1 5.1  Single  Rotterdam Criteria  12  NA    CPA+EE+MET  2 mg/day+35 \u03bcg/day+850 mg bid  12  24.9 \u00b1 4.8    CC  100 mg/day  15  28.0 \u00b1 1.1 *  MET  850 mg bid  12  24.4 \u00b1 6.2    CPA+EE+SPR  2 mg/day+35 \u03bcg/day+100 mg/day  12  23.4 \u00b1 5.8     Kebapcilar et al,   2009  Turkey  CPA+EE  2 mg/day+35 \u03bcg/day  22  24.1 \u00b1 5.6  Single  Rotterdam Criteria  12  NA   Kazerooni et al,   2010  United States  MET+SMV  500 mg tid+20 mg/day  42  25.6 \u00b1 4.32  Double  Rotterdam Criteria  12  NA    CPA+EE+MET  2 mg/day+35 \u03bcg/day+1700 mg/day  21  25.1 \u00b1 1.4  MET+PLC  500 mg tid  42  24.9 \u00b1 5.81     Kazerooni et al,   2009  United States  CC+MET  100 mg/day+500 mg tid  20  24.5 \u00b1 5.16  Double  Rotterdam Criteria  4  CC   Kaya et al,   2015  Turkey  DPN+EE  3 mg/day+3 \u03bcg/day  25  23.0 \u00b1 5.0  Double  Rotterdam Criteria  24  NA    CC+PLC  100 mg/day  20  25.47 \u00b1 4.7  DPN+EE+MET  3 mg/day+3 \u03bcg/day+850 mg bid  25  24.0 \u00b1 4.0     Kaya et al,   2012  Turkey  DPN+EE  3 mg/day+3 \u03bcg/day  19  23.2 \u00b1 5.4  Double  Androgen Excess Society criteria  24  NA   Karimzadeh et al,   2007  Iran  MET  500 mg tid  100  27.2 \u00b1 6.8  Double  Rotterdam Criteria  12  NA    DPN+EE+MET  3 mg/day+3 \u03bcg/day+850 mg bid  18  23.0 \u00b1 4.5  PLC   100  28.6 \u00b1 7.4     Ko et al,   2001    500 mg tid    Single  NIH Criteria     Lord et al,   2006  United Kingdom  MET  500 mg tid  21  27.76 \u00b1 4.89  Double  Rotterdam Criteria  12  NA        PLC   19  30.63 \u00b1 4.84     De Leo et al,   2013  Italy  INS 1 +MNK  1.5 g/day+3 g bid  20  24 to 32  Single  Rotterdam Criteria  24  NA   Lemay et al,   2006  Canada  RGZ  4 mg/day  10  26.8 \u00b1 5.7  Single  Rotterdam Criteria  24  NA    INS 1  1.5 g/day  20  24 to 32    CPA+EE  2 mg/day+35 \u03bcg/day  7  20.0 \u00b1 1.5    MET  850 mg bid  20  24 to 32     Legro et al,   2014  United States  CC  50 mg/day  376  28.8 \u00b1 4.0  Double  Rotterdam Criteria  16  NA   Legro et al,   2007  United States  CC+PLC  50 mg/day  209  27.9 \u00b1 4.0  Double  NIH criteria and Rotterdam diagnostic criteria  24  NA    MET+PLC  500 mg tid  208  28.1 \u00b1 4.0    LET  2.5 mg/day  374  28.9 \u00b1 4.5    CC+MET  50 mg/day+500 mg tid  209  28.3 \u00b1 4.0     Ladson et al,   2011  United States  MET  500 mg bid    Double  NIH Criteria  24  NA   Morin-Papunen et al,   2000  Finland  MET  1000 mg bid  16  29.9 \u00b1 1.5 *  Single  NIH Criteria  24  NA    PLC   59  28.8 \u00b1 4.6  CPA+EE  2 mg/day+35 \u03bcg/day  16  28.8 \u00b1 1.0 *     Moini et al,   2015  Iran  ORL  120 mg tid  50  26.8 \u00b1 5.16  Double  Rotterdam Criteria  12  NA   Mohsen et al,   2012  Egypt  CC+RGZ  100 mg+4 mg bid  46  25.9 \u00b1 2.7  Single  Rotterdam Criteria  12  NA    PLC   50  27.42 \u00b1 3.31  CC  100 mg/day  45  26.4 \u00b1 2.9     Mohiyideen et al,   2013  United Kingdom  RGZ  4 mg od  18  29.0 \u00b1 1.0  Double  Rotterdam Criteria  12  NA   Moghetti et al,   2000  Italy  MET  500 mg tid  12  23.9 \u00b1 1.2 *  Double  NIH Criteria  24  NA    MET  500 mg bid  17  30.0 \u00b1 0.9  PLC   11  21.4 \u00b1 1.4 *     Mehrabian et al,   2016  Iran  MET  1000 mg/day  37  29.18 \u00b1 8.288  Single  NIH Criteria  24  NA   Machado et al,   2012  Brazil  MET  850 mg bid  21  27.4 \u00b1 3.8  Double  Rotterdam Criteria  8  NA    EE+FLT+LVT  0.03 mg/day +62.5 mg/day+0.15 mg/day  37  29.0 \u00b1 7.663    PLC   15  28.2 \u00b1 3.2    SMV  20 mg/day  37  29.15 \u00b1 8.261     Nylander et al,   2017  Denmark  LIR  1.8 mg/day  48  31.4 (24.6\u201335.6) ***  Double  Rotterdam Criteria  26  NA   Nestler et al,   1999  United States  INS 2  1200 mg/day  22  29.0 \u00b1 6.0  Double  NIH Criteria  6 to 8  NA    PLC   24  26.2 (24.8\u201331.5) ***  PLC   22  26.0 \u00b1 5.0     Nestler et al,   1998  United States  MET  500 mg tid  35  29.0 \u00b1 1.0 *  Single  NIH Criteria  5  NA   Nordio et al,   2012  Italy  INS 1  550 mg bid  24  28.2 \u00b1 1.5  Single  Rotterdam Criteria  24  NA    PLC   26  28.0 \u00b1 1.0 *  INS 1 +INS 2  550 mg bid+13.8 mg bid  26  27.9 \u00b1 1.4     Onalan et al, (a)   2005  Turkey  MET  500\u2013850 mg bid  10  24.6 \u00b1 4.8  Double  NIH Criteria  24  NA   Onalan et al, (b)   2005  Turkey  MET  500\u2013850 mg bid  10  31.8 \u00b1 4.0  Double  NIH Criteria  24  NA    PLC   9  27.3 \u00b1 4.4  PLC   8  21.2 \u00b1 5.5     Pasquali et al, (4 wks)   2000  Italy  MET  850 mg bid  12  31.6 \u00b1 10.3  Double  NIH Criteria  4  NA   Pasquali et al, (28 wks)   2000  Italy  MET  850 mg bid  20  31.6 \u00b1 10.3  Double  NIH Criteria  28  NA    PLC   8  36.3 \u00b1 9.5  PLC   20  36.3 \u00b1 9.5     Parsanezhad et al, (12 wks)   2004  Iran  BRM+CC  7.5 mg/day+150 mg/day  47  25.02 \u00b1 2.7  Double  NIH Criteria  12  CC   Parsanezhad et al, (24 wks)   2004  Iran  BRM+CC  7.5 mg/day+150 mg/day  47  25.02 \u00b1 2.7  Double  NIH Criteria  24  CC    CC+PLC  150 mg/day  53  24.87 \u00b1 2.9  CC+PLC  150 mg/day  53  24.87 \u00b1 2.9     Parsanezhad et al,   2002  Iran  CC+DEX  200 mg/day+2 mg/day  20  23.56  Double  NIH Criteria  3  CC   Rautio et al, (12 wks)   2005  Finland  MET  500\u20131000 mg bid  16  29.6 \u00b1 1.1 *  Single  Rotterdam Criteria  12  NA    CC+PLC  200 mg/day  20  23.36  CPA+EE  2 mg+0.035 mg  16  29.6 \u00b1 1.1 *     Rautio et al, (24 wks)   2005  Finland  MET   16  29.6 \u00b1 1.1 *  Single  Rotterdam Criteria  24  NA   Rautio et al,   2006  Finland  RGZ  4\u20138 mg/day  15  26.7 \u00b1 1.1 *  Double  Rotterdam Criteria  16  NA    CPA+EE   16  29.6 \u00b1 1.1 *  PLC   15  30.1 \u00b1 2.1 *     Rautio et al,   2007  Finland  RGZ  4\u20138 mg/day  12  29.1 \u00b1 1.2 *  Double  Rotterdam Criteria  16  NA   Rouzi et al,   2006  Saudi Arabia  CC+RGZ  100 mg/day+4 mg bid  12  28.58 \u00b1 3.73  Single  NIH Criteria  12  CC    PLC   14  29.1 \u00b1 1.2 *  CC+MET  100 mg/day+500 mg tid  13  27.38 \u00b1 4.29     Sova et al,   2013  Finland  MET  1000 mg bid  23  29.2 \u00b1 4.6  Double  Rotterdam Criteria  12  NA   S\u00f6nmez et al,   2005  Turkey  ACR+CC  300 mg/day+100 mg/day  15  26.13 \u00b1 5.08  Double  NIH Criteria  12  CC    PLC   27  27.4 \u00b1 4.9  CC+MET  100 mg/day+1700 mg/day  15  26.0 \u00b1 3.92     Song et al,   2018  China  CPA+EE+ORL  2 mg/day+35 \u03bcg/day+120 mg tid  60  26.77 \u00b1 4.12  Double  Rotterdam Criteria  12  NA   Sathyapalan et al,   2010  United Kingdom  ATR+MET  20 mg/day+500 mg tid  19  26.6 \u00b1 1.2 *  Double  NIH Criteria  24  NA    CPA+EE+MET  2 mg/day+35 \u03bcg/day+500\u20131500 mg/day  60  28.63 \u00b1 5.12    CPA+EE+MET+ORL  2 mg/day+35 \u03bcg/day+500\u20131500 mg/day+120 mg tid  60  27.57 \u00b1 4.58  MET+PLC  500 mg tid  18  28.8 \u00b1 1.8 *    CPA+EE  2 mg/day+35 \u03bcg/day  60  27.68 \u00b1 4.99     Tfayli et al,   2011  United States  DPN+EE  3 mg/day+30 \u03bcg/day  20  16.2 \u00b1 0.3 *  Double  NIH Criteria  24  NA   Tang et al,   2006  United Kingdom  MET  850 mg bid  69  29.7 \u00b1 3.7  Double  Rotterdam Criteria  24  NA    RGZ  4 mg/day  17  15.7 \u00b1 0.3 *  PLC   74  29.8 \u00b1 3.8     Villaseca et al,   2004  Chile  MPA  10 mg/day  15  23.9 \u00b1 5.1  Single  NIH Criteria  12  NA   Vanky et al, (a)   2004  Norway  MET+PLC  850 mg tid  15  28.3 \u00b1 5.0  Double  Rotterdam Criteria  8  NA    BRM+MET  5 mg/day+850 mg tid  14  28.3 \u00b1 5.0    CPA+EE  2 mg/day+35 \u03bcg/day  16  22.4 \u00b1 6.1    DEX+MET  0.5 mg/day+850 mg tid  12  28.3 \u00b1 5.0     Vanky et al, (b) (8 wks)   2004  Norway  DEX+MET  0.5 mg/day+850 mg tid  18  26.4 \u00b1 3.8  Double  Rotterdam Criteria  8  NA   Vanky et al, (b) (26 wks)   2004  Norway  DEX+MET  0.5 mg/day+850 mg tid  18  26.4 \u00b1 3.8  Double  Rotterdam Criteria  26  NA    MET+PLC  850 mg tid  20  30.6 \u00b1 5.9  MET+PLC  850 mg tid  20  30.6 \u00b1 5.9     Vandermolen et al,   2001  United States  MET  500 mg tid  11  29.0 \u00b1 1.2 *  Double  NIH Criteria  7  CC   Van Santbrink et al,   2005  The Netherlands  MET  850 mg bid  11  28.0 (22\u201332) ****  Double  NIH Criteria  5  NA    PLC   14  30.0 \u00b1 1.0 *  PLC   9  28.0 (24\u201334) ****     Wu et al,   2008  China  CPA+EE  2 mg/day+35 \u03bcg/day  7  25.0 \u00b1 4.3  Double  Rotterdam Criteria  12  NA   Yarali et al,   2002  Turkey  MET  850 mg bid  16  29.7 \u00b1 5.6  Double  NIH Criteria  6  CC    MET  500 mg tid  7  25.6 \u00b1 3.6    PLC   16  28.4 \u00b1 5.1    CPA+EE+MET  2 mg/day+35 \u03bcg/day+500 mg tid  6  24.5 \u00b1 2.4     Yilmaz et al,   2005  Turkey  MET  850 mg bid  43  24.67 \u00b1 4.6  Single  Rotterdam Criteria  24  NA   Zheng et al,   2019  China  EXN  10 \u03bcg bid  31  27.2 \u00b1 1.76 *  Single  Rotterdam Criteria  12  NA    RGZ  4 mg/day  45  25.13 \u00b1 4.43  MET  1000 mg bid  32  27.7 \u00b1 1.64 *"
        }
    ],
    "images": [
        {
            "caption": "A PRISMA flow diagram illustrates the search results, de-duplication, screening and the selection process."
        },
        {
            "caption": "Network graphs of eligible comparisons for efficacy.  The size of the circles is proportional to sample size, and the width of lines is proportional to the number of trials. Interventions: acarbose (ACR), alfacalcidol (ALF), anastrozole (ANZ), clomiphene citrate (CC), exenatide (EXN), folic acid (FA), flutamide (FLT) pure follicle-stimulating hormone (FSH), human menopausal gonadotropins (HMG), inositol (INS), letrozole (LET), liraglutide (LIR), metformin (MET), medroxyprogesterone acetate (MPA), N-acetyl cysteine (NAC), orlistat (ORL), pioglitazone (PGZ), placebo (PLC), rosiglitazone (RGZ), sibutramine (SBT), simvastatin (SMV), and troglitazone (TGZ). Acarbose+clomiphene citrate (ACR+CC), alfacalcidiol+metformin (ALF+MET), atorvastatin+metformin (ATR+MET), bromocriptine+clomiphene citrate (BRM+CC), bromocriptine+metformin (BRM+MET), clomiphene citrate+dexamethasone (CC+DEX), clomiphene citrate+ketoconazole (CC+KTZ), clomiphene citrate+l-carnitine (CC+LC), clomiphene citrate+l-carnitine+metformin (CC+LC+MET), clomiphene citrate+metformin (CC+MET), clomiphene citrate+N-acetylcysteine (CC+NAC), clomiphene citrate+rosiglitazone (CC+RGZ), chlormadinone acetate+ethinylestradiol (CHA+EE), cyproterone acetate+ethinylestradiol (CPA+EE), cyproterone acetate+ethinylestradiol+metformin (CPA+EE+MET), cyproterone acetate+ethinylestradiol+metformin+orlistat (CPA+EE+MET+ORL), cyproterone acetate+ethinylestradiol+orlistat (CPA+EE+ORL), cyproterone acetate+ethinylestradiol+spironolactone (CPA+EE+SPR), dexamethasone+metformin (DEX+MET), desogestrel+ethinylestradiol (DGT+EE), drospirenone+ethinylestradiol (DPN+EE), drospirenone+ethinylestradiol+metformin (DPN+EE+MET), ethinylestradiol+flutamide+levonorgestrel (EE+FLT+LVT), ethinylestradiol+gestodene (EE+GTN), ethinylestradiol+metformin+norgestimate (EE+MET+NRG), ethinylestradiol+norgestimate (EE+NRG), folic acid+inositol (FA+INS), flutamide+metformin (FLT+MET), human menopausal gonadotropins+ leuprolide (HMG+LPR), inositol+monacolin k (INS+MNK), letrozole+metformin (LET+MET), metformin+rosuvastatin (MET+RSV), and metformin+simvastatin (MET+SMV)."
        },
        {
            "caption": "Forest plots show the mean difference (MD) of different interventions compared with placebo for each outcome, along with the associated 95% CI.  Interventions: acarbose (ACR), alfacalcidol (ALF), anastrozole (ANZ), clomiphene citrate (CC), exenatide (EXN), folic acid (FA), flutamide (FLT) pure follicle-stimulating hormone (FSH), human menopausal gonadotropins (HMG), inositol (INS), letrozole (LET), liraglutide (LIR), metformin (MET), medroxyprogesterone acetate (MPA), N-acetyl cysteine (NAC), orlistat (ORL), pioglitazone (PGZ), placebo (PLC), rosiglitazone (RGZ), sibutramine (SBT), simvastatin (SMV), and troglitazone (TGZ). Acarbose+clomiphene citrate (ACR+CC), alfacalcidiol+metformin (ALF+MET), atorvastatin+metformin (ATR+MET), bromocriptine+clomiphene citrate (BRM+CC), bromocriptine+metformin (BRM+MET), clomiphene citrate+dexamethasone (CC+DEX), clomiphene citrate+ketoconazole (CC+KTZ), clomiphene citrate+l-carnitine (CC+LC), clomiphene citrate+l-carnitine+metformin (CC+LC+MET), clomiphene citrate+metformin (CC+MET), clomiphene citrate+N-acetylcysteine (CC+NAC), clomiphene citrate+rosiglitazone (CC+RGZ), chlormadinone acetate+ethinylestradiol (CHA+EE), cyproterone acetate+ethinylestradiol (CPA+EE), cyproterone acetate+ethinylestradiol+metformin (CPA+EE+MET), cyproterone acetate+ethinylestradiol+metformin+orlistat (CPA+EE+MET+ORL), cyproterone acetate+ethinylestradiol+orlistat (CPA+EE+ORL), cyproterone acetate+ethinylestradiol+spironolactone (CPA+EE+SPR), dexamethasone+metformin (DEX+MET), desogestrel+ethinylestradiol (DGT+EE), drospirenone+ethinylestradiol (DPN+EE), drospirenone+ethinylestradiol+metformin (DPN+EE+MET), ethinylestradiol+flutamide+levonorgestrel (EE+FLT+LVT), ethinylestradiol+gestodene (EE+GTN), ethinylestradiol+metformin+norgestimate (EE+MET+NRG), ethinylestradiol+norgestimate (EE+NRG), folic acid+inositol (FA+INS), flutamide+metformin (FLT+MET), human menopausal gonadotropins+ leuprolide (HMG+LPR), inositol+monacolin k (INS+MNK), letrozole+metformin (LET+MET), metformin+rosuvastatin (MET+RSV), and metformin+simvastatin (MET+SMV)."
        },
        {
            "caption": "A rankogram show the cumulative ranking of the average SUCRA values for each intervention across all metabolic and hormonal parameters."
        }
    ]
}